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Abbreviations and definitions 
AUDADIS: Alcohol Use Disorder and Associated Disabilities Interview Schedule 
AUDIT: Alcohol Use Disorders Identification Test 
CIDI: Composite International Diagnostic Interview 
Comorbidity: Co-occurring mental disorders and substance use disorders; see below. 
Co-occurring disorder (COD): A term interchangeably used with dual diagnosis or 
comorbidity; it refers to individuals who “have one or more substance-related disorders as 
well as one or more mental disorders” (Co-occurring Center for Excellence, 2007) (1). 
DIS: Diagnostic Interview Schedule 
Drugs: Prescribed medication used in a non-prescribed way, medication gained illegally, and 
the different illegal psychoactive drugs. Drugs include opioids, cannabinoids, 
sedatives/hypnotics, cocaine, stimulants, hallucinogens, and “other” drugs (e.g., volatile 
solvents, steroids, GHB). 
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
Dual diagnosis: Co-occurring disorder or comorbidity; see above. 
DUDIT: Drug Use Disorders Identification Test 
ECA: Epidemiologic Catchment Area Study 
EuropASI: European version of the Addiction Severity Index 
GAF: Global Assessment of Functioning scale 
ICD-10: International Classification of Diseases, Tenth Edition 
Independent mental disorders: Mental disorders that begin prior to the onset of heavy 
substance use or occur during extended abstinence. 
LC-MS: Liquid chromatography-mass spectroscopy 
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Mental disorders: Disorders defined according to the nomenclature in the International 
Classification of Diseases (ICD-10, chapter F0-F9) and the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV) (2;3). 
MDE: Major Depressive Episode 
MINI: MINI International Neuropsychiatric Interview 
NESARC: National Epidemiologic Survey on Alcohol and Related Conditions  
PANSS: Positive and Negative Syndrome Scale  
PRISM: Psychiatric Research Interview for Substance and Mental Disorders 
PTSD: Post-traumatic Stress Disorder 
SCAN: Schedules for Clinical Assessment in Neuropsychiatry 
SCID: Structured Clinical Interview for DSM-IV disorders 
SMI: Severe Mental Illness 
Substance: A collective term referring to both alcohol and drugs 
Substance-induced mental disorders: Mental disorders that occur entirely during a period of 
heavy substance use or within the first weeks after cessation of use. The substance effects can 
cause symptoms mimicking the disorder being assessed, and the symptoms are greater than 
the expected effects of intoxication and/or withdrawal. 
SUD:  Substance Use Disorder is a collective term referring to the two diagnoses Substance 
Abuse and Substance Dependence according to the classification in DSM-IV, see criteria 
below. 
WHO: World Health Organization  
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Criteria for Substance Dependence according to the DSM-IV criteria (3) 
A maladaptive pattern of substance use, leading to clinically significant impairment or 
distress, as manifested by three (or more) of the following, occurring at any time in the same 
12-month period: 
(1) Tolerance, as defined by either of the following: 
(a) a need for markedly increased amounts of the substance to achieve intoxication or        
desired effect 
(b) markedly diminished effect with continued use of the same amount of the 
substance 
(2) withdrawal, as manifested by either of the following: 
(a) the characteristic withdrawal syndrome for the substance (refer to Criteria A and B 
of the criteria sets for Withdrawal from the specific substances) 
(b) the same (or a closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
(3) the substance is often taken in larger amounts or over a longer period than was 
intended 
(4) there is a persistent desire or unsuccessful efforts to cut down or control substance use 
(5) a great deal of time is spent in activities necessary to obtain the substance (e.g., 
visiting multiple doctors or driving long distances), use the substance (e.g., chain-
smoking), or recover from its effects 
(6) important social, occupational, or recreational activities are given up or reduced 
because of substance use 
(7) the substance use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated by 
the substance (e.g., current cocaine use despite recognition of cocaine-induced 
depression, or continued drinking despite recognition that an ulcer was made worse by 
alcohol consumption) 
 
Specify if: 
With Physiological Dependence:  evidence of tolerance or withdrawal (i.e., either 
Item 1 or 2 is present) 
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Without Physiological Dependence:  no evidence of tolerance or withdrawal (i.e., 
neither Item 1 nor 2 is present) 
 
Criteria for Substance Abuse according to the DSM-IV criteria 
A. A maladaptive pattern of substance use leading to clinically significant impairment or 
distress, as manifested by one (or more) of the following, occurring within a 12-month 
period: 
 
(1)  recurrent substance use resulting in a failure to fulfill major role obligations at 
work, school, or home (e.g., repeated absences or poor work performance related to 
substance use; substance-related absences, suspensions, or expulsions from school; 
neglect of children or household) 
(2)  recurrent substance use in situations in which it is physically hazardous (e.g., 
driving an automobile or operating a machine when impaired by substance use) 
(3)  recurrent substance-related legal problems (e.g., arrests for substance-related 
disorderly conduct) 
(4)  continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance (e.g., 
arguments with spouse about consequences of intoxication, physical fights) 
   B. The symptoms have never met the criteria for Substance Dependence for this class of 
substance. 
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Summary 
Background: Substance use disorders (SUDs) often co-occur with mental disorders.  Both 
epidemiological and clinical surveys have shown an increasing prevalence of this type of 
comorbidity in recent years. In clinical settings, comorbidity represents challenges for 
diagnosis and treatment. This is particularly serious in acute psychiatric wards where 
substance use is prevalent among the patients.  When SUDs and mental disorders co-exist, a 
deteriorating clinical course often follows. Optimal treatment requires knowledge of the 
etiology and reciprocity of the different disorders and diagnostic accuracy. The biological 
effects of abused substances may independently cause psychiatric symptoms which make 
diagnosis especially challenging. Better methods for investigating SUDs in subjects with 
mental disorders and better comorbidity diagnostics are needed.  
Objectives: The first aim was to investigate the rate and types of SUDs in a group of 
psychotic inpatients from a specific catchment area. We wanted to estimate the current and 
lifetime prevalence of problematic substance use and SUDs in this specific patient group. 
Also, we wanted to see whether patients’ self-report of recent substance use was in 
concordance with the results of toxicology screens. The second aim was to study diagnostic 
issues in psychotic and mood disordered patients with substance use admitted to an acute 
psychiatric ward. The main focus in this regard was differentiation between independent 
disorders complicated with SUDs and substance-induced disorders. 
Methods: This thesis consists of two studies. The first is a prevalence study that was 
conducted in 65 psychotic patients using the Addiction Severity Index (EuropASI), the 
Structured Clinical Interview for DSM-IV disorders (SCID-I) and blood and urine toxicology 
screens. Patients were 40 years and younger and they were admitted to Blakstad Psychiatric 
Hospital, Norway, in 2001. In the second study, the main focus was investigating the 
diagnostic issues when SUDs co-occur with mental disorders. The American semi-structured 
interview, Psychiatric Research Interview for Substance and Mental Disorders (PRISM), was 
translated into Norwegian. The translation was done according to recommended guidelines. 
The PRISM interview was then conducted on 61 patients admitted with substance use and 
presenting mood symptoms, psychotic symptoms, or both. Patients were aged 18-65 years and 
they were admitted to the acute psychiatric ward in Blakstad Hospital in 2007/2008. Variables 
pertaining to various feasibility measures of the PRISM were recorded. Further, the findings 
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of heavy substance use, SUDs, and independent versus substance-induced mood and 
psychotic disorders were recorded.  
Results: In study I, we found that 54% of the younger psychotic patients reported having used 
one or more substances for intoxication during the month prior to admission. 40% of the 
patients had used illegal drugs, mostly cannabis and amphetamine. Toxicology screens 
confirmed patients’ self- report of recent substance use. Current and lifetime rates of SUDs in 
patients were 50% and 70%, respectively. In study II, we found that it was possible to use the 
PRISM systematically with psychotic and mood disordered patients in a busy acute 
psychiatric ward. 51% of eligible patients were interviewed, and median interview time was 
155 minutes. The PRISM showed that current major depressive episodes (MDEs) were 
substance-induced in 72% of patients with MDE, of which 57% were alcohol-induced. 
Current psychotic disorders were substance-induced in approximately one third of patients 
with psychotic disorders. The substances most often used heavily were alcohol, cannabis and 
stimulants. 
Conclusion: Heavy substance use and SUDs are prevalent in psychotic patients. The level of 
comorbidity is comparable with that found in American studies, despite lower prevalence of 
substance use in the Norwegian population. The high rate of SUDs in psychotic inpatients has 
implications for the treatment and the organization of psychiatric care for these patients.  
The PRISM was feasible in an acute psychiatric ward. The PRISM provided detailed, 
clinically significant diagnoses in patients hospitalized for acute mental disorder with 
concurrent substance use. It was possible to differentiate between independent and substance-
induced mood and psychotic disorders. Diagnostic accuracy is important for targeted 
treatment.  
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1. Introduction 
During the late 1990s, when I was working as a senior consultant in one of the wards 
specializing in long term treatment of psychotic disorders at Blakstad Hospital, we 
encountered a steadily rising increase in substance use problems among our patients.  Even 
though there was no particular focus on substance use then, this problem area challenged both 
the individual therapies and the ward atmosphere. Further, I found little knowledge about this 
comorbidity in the Norwegian psychiatric field at that time. This provoked my curiousity 
since I regarded the increasing substance use as one of the main professional challenges in our 
daily clinical work. The focus was not on occasional substance use but on use which had 
clinical implications. First, I wanted to find out how many of the younger psychotic patients 
admitted to the hospital had substance use problems. During this investigation, the focus was 
on the methods used for detecting substance use in psychiatric patients. We found a high 
prevalence of this comorbidity; the prevalence was comparable to that of other Western 
countries. However, as we studied prevalence numbers, a diagnostic problem gradually 
emerged. When individuals with mental disorders also use substances, how can a 
differentiation be made between symptoms complicated by substance use but basically caused 
by the primary (=independent) mental disorders, and those symptoms which are substance-
induced? Clinically, this issue was regularly exemplified in the challenge of distinguishing 
schizophrenia with concomitant substance use from a substance-induced psychosis. These 
considerations led me to the US-developed Psychiatric Research Interview for Substance and 
Mental Disorders (PRISM) which was constructed to differentiate between primary and 
substance-induced mental disorders in subjects who abuse substances. PRISM was chosen as 
the structured diagnostic interview for further comorbidity research. The interview was 
translated into Norwegian and the Norwegian version was used at Blakstad Hospital to study 
its feasibility among acute psychiatric ward patients with mood and psychotic disorders and 
concurrent substance use. Independent and substance-induced disorders were diagnosed 
according to the PRISM. The results from this study will hopefully contribute to better 
understanding and a more nuanced picture of the comorbidity of mental disorders and 
substance use disorders, and better understanding leads to better treatment.  
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1.1 Prevalence of co-occurring substance use disorders (SUDs) and non-SUD mental 
disorders  
During recent decades, there has been growing concern about the high prevalence of co-
occurring SUDs and mental disorders. Epidemiological surveys have shown that individuals 
with mood disorders, psychotic disorders, anxiety disorders and personality disorders have 
high rates of SUD comorbidity (4-21).  Numerous clinical studies have also shown a high 
prevalence of SUDs in patients with mental disorders; prevalence varies with methodology 
and type of clinical setting. In psychiatric emergency services and in acute psychiatric wards 
several studies have shown high prevalence of substance use among the patients admitted (22-
28). In a Norwegian acute psychiatric ward study, psychoactive substances were detected by 
toxicology screening in 63% of admissions (28). Further, a study from Hordaland county 
showed that the annual number of inpatients with a drug/alcohol problem increased fivefold 
in the period from 1985 to 2003 (29). Clinical studies have shown SUDs to be prevalent in 
mood disorders (30-32). In this thesis, the prevalence of SUD in psychotic inpatients was one 
of the research questions. A vast number of studies exist on psychotic disorders and co-
occurring SUDs. Studies from various clinical settings have shown high prevalence of 
substance use in these patients (33-40). The findings reported in European clinical surveys of 
psychotic patients vary to a degree that makes interpretation difficult (33;37;41;42). British 
clinical surveys, for instance, have shown rates of substance use problems or substance use 
disorders ranging from 7% to 49% (34;37;41;43;44). In French and German studies, lifetime 
prevalence of substance use disorders has been reported to range from 22% to 48% 
(33;45;46). Scandinavian studies have a more homogenous pattern, but few studies have been 
published. In a Swedish study of both inpatients and outpatients with DSM-IV diagnoses of 
schizophrenia, the lifetime prevalence of substance abuse was 48% (42). In a Danish study of 
psychiatric inpatients, the prevalence of co-occurrence between substance use disorders and 
mental disorders other than substance use disorder was 37% (47). Here, however, all types of 
diagnostic categories, not only patients with psychotic disorders, were included. Studies from 
first-episode psychosis and early intervention samples have shown substance abuse ranging 
from 15% to 74% (38;39;44;48-50). The prevalence rates vary according to whether current 
or lifetime numbers are reported, and whether alcohol or drugs are reported. Data from two 
British epidemiologically based first-episode studies have shown a highly significant rise in 
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the prevalence of all SUDs over the 1990s in females with a first-episode psychosis aged 16-
29 (51).  
Subjects with SUDs and patients from the substance abuse services often present with co-
occurring mental disorders (52-55). In a Norwegian sample of alcohol dependent and poly-
substance dependent patients, the frequency of current social anxiety disorder was found to be 
42% (56). From the same sample of patients, the follow-up study showed that relapsers have 
an earlier onset of SUD, and more frequently have major depression and agoraphobia (57). 
Overall, individuals with both SUDs and mental disorders are frequently seen in various 
clinical settings both in psychiatry and in the substance abuse field. There is no doubt that co-
occurring substance use is a challenge in Norwegian inpatient psychiatric services as in other 
countries.  
 
1.2. Theories about the comorbidity – explanations and possible causations 
There are diverse and conflicting theories and associations which try to explain the high 
comorbidity of mental disorders and co-occurring SUDs (6;58-68). Patients may use 
substances to alleviate mental symptoms or side effects of medication; the abused substances 
might cause mental symptoms; there might be genetic risk factors and psychosocial risk 
factors, and there might be interactions between these different comorbidity mechanisms. The 
self-medication hypothesis explains patients’ use of substances as an effort to reduce 
symptoms of the disorder (69;70), or to lessen the side effects of antipsychotic medication 
(71;72). The self-medication hypothesis, described by Khantzian, claims that individuals with 
SUDs suffer with their feelings. According to this theory, these individuals use substances to 
relieve painful affects, to experience desired emotions, or to control emotions when they are 
confusing (69;70). A recent paper reviewed the literature relating to self-reported reasons and 
motives for alcohol use in bipolar disorders (73). The findings there supported the notion that 
alcohol was used to relieve distressing mood states. Data from the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC) revealed that approximately 20% of 
individuals with Post-traumatic Stress Disorder (PTSD) used substances in an attempt to 
relieve their symptoms (74). Also, NESARC data showed comorbid Major Depressive 
Episode (MDE) to be associated with higher prevalence of drinking to enhance depressed 
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mood (75). The biological effects of the abused substances may independently cause 
psychiatric symptoms (3;76-78) and brain changes that develop during substance dependence 
may express psychiatric symptoms (79;80). Further, advances in neurobiology suggest that 
the neuropathology of schizophrenia affects the neural circuitry mediating drug reward. This 
leads to an increased vulnerability to both addiction and psychotic symptoms (81). In a 
population-based registry study, multivariate twin modeling analyses indicated that the 
pattern of lifetime comorbidity of common mental disorders and SUDs originates largely 
from genetic risk factors (82). In a recent study, abnormalities in fronto-striatal brain systems 
implicated in self-control were found in both stimulant-dependent individuals and their 
biological siblings without SUD (83). The authors therefore suggest an underlying 
neurocognitive endophenotype for stimulant drug addiction.  
Mueser et al have previously reviewed the etiological theories on dual diagnosis (84). This 
review states that, “There is minimal support for the self-medication hypothesis, but the 
accumulation of multiple risk factors related to mental illness, including dysphoria, may 
increase the risk of substance use disorder”. The authors claim that among secondary 
substance use disorder models, there is support for the supersensitivity model. This model 
suggests that some excess comorbidity of severe mental illness and SUDs can be accounted 
for by increased biological vulnerability to the effects of alcohol and drugs (60;84). However, 
a more recent study did not find support for the supersensitivity hypothesis (85). The various 
substances might have different impact on the etiological mechanisms involved in comorbid 
disorders. A recent paper reports variations in the reasons for use of different substances 
across people with different mental disorders (86). While alcohol was primarily used to cope, 
cannabis was primarily used for pleasure. For participants with psychotic disorders, tobacco 
played an important role; whereas for participants with depression, alcohol appeared to play 
an important role (86). In fact, mental disorders might be complicated by, but etiologically 
independent of, substance use, or mental disorders might be induced by substance use. 
To summarize, the interaction model still seems to be the prevailing explanation for the 
highly prevalent co-occurrence of SUDs and mental disorders. There is an intricate interaction 
between substance use and mental disorders.  SUDs might lead to mental disorders, and 
mental disorders might lead to SUDs. The combination of biological circumstances and 
mental problems linked to substance use take various forms in different subjects. Each person 
has their own mixture of these factors. Therefore, it is of vital importance to explore these 
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issues in dual diagnosis patients and thoroughly map the contribution of substance use and 
mental disorder symptoms in each patient. Appropriate diagnostic measures are of great 
importance in this.  
 
1.3. Clinical course of co-occurring SUDs and mental disorders 
Generally, in subjects with mental disorders, substance use complicates both diagnostic 
procedures and treatment, and a deteriorating clinical course often follows. Patients with 
mental disorder and co-occurring SUDs might be more difficult to reach for therapy, and 
substance use might interact negatively with underlying vulnerabilities. Studies have shown 
dual diagnosis patients to have higher frequencies of hospitalization (31;87;88). Symptoms of 
mental disorders might be induced or exaggerated by the chemical effects of the various 
substances; e.g., stimulants and cannabis can be causally linked to the development of 
psychotic symptoms (89-96). Studies have shown that substance use may cause functional 
impairment and more severe symptoms in schizophrenia (42;97;98). Findings from the 
CATIE study sample (Clinical Antipsychotic Trials of Intervention Effectiveness) suggested 
that drug-use-related impairment, comorbid with schizophrenia, may not be a function of use 
per se but rather, of the severity of use (99). A 15-year follow-up study from Denmark found 
patients with schizophrenia and SUD to have a significantly elevated usage of all types of 
hospital contacts except inpatient treatment for non-psychiatric disorders (100). A history of 
substance misuse has been shown to be associated with earlier age of onset of schizophrenia 
(101), and persistent SUD in first-episode psychosis reduced the likelihood of remission (39). 
Studies have shown that comorbid psychotic patients have a higher risk of involuntary 
hospitalization than patients with psychosis alone (88;102).  
Study findings from an alcohol treatment setting showed that patients with comorbid anxiety 
and/or depressive disorders were more disabled and drank more heavily than those without 
these comorbid disorders at entry to treatment (103). In studies in people with bipolar 
disorder, SUD has been associated with more hospitalizations, medication non-compliance, 
greater risk of switch into manic, mixed, or hypomanic states and possibly an earlier onset of 
mood symptoms (104;105). Also, a study showed bipolar patients with SUD to have impaired 
social functioning, to the level observed in patients with schizophrenia, compared to bipolar 
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patients without SUD (106). Norwegian patients with bipolar disorder and excessive 
substance use had impaired functioning, but not a worse course of illness (107).  
Numerous studies have shown increased risk of suicidal behaviour and suicide attempts in 
subjects with co-occurring substance use disorders and mental disorders (108-112). Among 
substance dependent Norwegian patients, 47% reported lifetime suicide attempts; early onset 
and long duration of SUD were independently associated with being a suicide attempter 
(113). In the same patient sample, a high prevalence of suicide attempts was also found at six 
years follow-up both in patients still abusing substances and in sober patients (114). The study 
concluded that treatment of both mood disorders and SUDs is important.  
Increased risk of violent behaviour has been shown in individuals with bipolar disorder and 
schizophrenia with concomitant substance misuse/abuse (115-117). Hence, there should be 
routine risk assessments for violence and violence management when planning treatment for 
comorbid patients. 
Some have found less severe negative effects of substance use than in the studies mentioned 
above (118).  Some have, in fact, found more favourable outcomes, higher intellectual 
functioning and better social role functioning when comorbid patients were compared to those 
who never abused (119-121). Data from Norwegian patients showed that in bipolar disorder 
subjects, cannabis use was associated with better neurocognitive function, but the opposite 
was the case for the schizophrenia subjects (122). Further, less frontal impairment and fewer 
negative symptoms or no association with negative symptoms have been found when patients 
with psychosis and SUD have been compared with psychotic patients without SUD (102;123-
126).  
Generally, as far as inconsistencies in outcomes in patients with schizophrenia and SUD are 
concerned, the divergent findings can be attributed to methodological issues and the difficulty 
in differentiating aspects of SUD from schizophrenia symptoms. Also, studies mostly 
investigate ‘substance use’ as one entity, whereas use of cannabis only might have different a 
impact on the psychotic disorder than other substances (50). The proposed link between 
cannabis use and psychotic disorders (92;96;127;128), might lead to a subgroup of patients 
with better premorbid function than the vulnerable group.  It is also obvious that, with proper 
interventions, the less serious substance-induced mental disorders might remit more easily 
than severe mental disorders without SUD.   
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Overall, substance use challenges the diagnostic and treatment considerations in subjects with 
mental disorders. Earlier studies have shown various areas of complexity in these comorbid 
patients. The psychiatric services, both inpatient and outpatient, need competence regarding 
the influence of SUD on diagnostics and treatment. Further, optimal treatment needs optimal 
diagnostics. This thesis focuses on investigating substance use and SUDs in psychotic and 
mood disordered patients and how best to diagnose the mental disorders when SUDs are 
present.  
 
1.4. Methodology concerning the investigation of mental disorders with co-occurring 
SUDs 
Detecting SUDs in subjects with mental disorders: A Norwegian study found that community 
mental health centres lacked sufficient diagnostic routines and specific instruments to identify 
SUD (129). It has been known for a long time that SUD diagnoses have often been missed in 
psychiatric patients (130). Screening instruments are used to identify subjects who may have a 
disorder, whereas diagnostic instruments are used to identify disorders (131). When using 
screening instruments, it is important to check if the screening instrument assesses current or 
past problems, or both. The Norwegian Knowledge Centre for the Health Services has 
reviewed accuracy studies (articles published up to April 2007) concerning screening and 
diagnostic tests to uncover SUD in a population with severe mental illness (SMI) and to 
uncover SMI in a population with SUD (131). According to the evidence, the CAGE test (Cut 
down, Annoyed, Guilty, Eye opener) and the AUDIT (Alcohol Use Disorders Identification 
Test) are both able to identify alcohol use disorders (131-133). AUDIT has previously been 
shown to be quite sensitive and specific as a screening test for alcohol problems (134). 
AUDIT has also been tested in people with schizophrenia and found to be a reliable and valid 
screening instrument in this patient sample (135). Regarding screening instruments for drug 
use disorders, the report did not find any instruments tested for diagnostic accuracy. A 
systematic review (articles published up to February 2010) of 13 screening instruments for 
detecting illicit drug use/abuse that could be useful in general hospital wards, concluded that 
there is lack of evaluation of these instruments (136). However, the findings in a more 
recently published study support DUDIT as a reliable and valid drug abuse screening 
instrument that measures a unidimensional construct (137). An AUDIT/DUDIT study of 
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Swedish suspected offenders with signs of mental health problems showed these screening 
tools to have moderate to high accuracy for identification of dependence diagnoses (138).  On 
the other hand, the validity of self-reported substance use might always be questioned and the 
necessity of validating self-report against biological tests is often pointed out (139;140).  
From the high comorbidity numbers, substance screening in various clinical settings seems 
warranted. An American study examined 16-year predictors of SUD diagnoses for patients 
with mental health disorders (141). Patients diagnosed with a SUD after baseline psychiatric 
hospitalization were more likely to have more medical hospitalizations and to be diagnosed 
with schizophrenia compared to those who were diagnosed with a SUD, including co-
occurring disorders, at baseline hospitalization. The authors conclusion is that there is a need 
to refine the evaluation of inpatient screening for SUD in health and mental health care units, 
and a need to reevaluate substance use at various times during inpatient care (141).   
The diagnostic instruments clarify whether the subject meets the diagnostic criteria for DSM-
IV substance abuse (ICD-10: harmful use) and/or dependence. The WHO study on the 
reliability and validity of SUD instruments tested the CIDI, the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN), and a special version of the Alcohol Use Disorder 
and Associated Disabilities Interview schedule-alcohol/drug-revised (AUDADIS-ADR) 
(142). Overall the diagnostic concordance coefficients were good for dependence disorders, 
but were somewhat lower for abuse and harmful use categories (142). The validity and 
reliability of the abuse/harmful use diagnosis is repeatedly shown to be lower than for the 
dependence diagnosis (143;144). Several authors have emphasized the problems with the 
abuse diagnosis (145-147). Subjects might have substance dependence diagnosis without 
abuse of the same substance (146). Therefore, using abuse symptoms as a screen for 
dependence might underestimate the prevalence of dependence (146;148;149). A dimensional 
option for the SUDs in DSM-V has been proposed, and plans to revise the SUD criteria are 
under consideration (145;147;150-152).  
Diagnosing mental disorders with co-occurring/complicating SUDs: Structured diagnostic 
interviews were first used to standardize data collection in epidemiology studies. Later they 
have been extensively used to ensure diagnostic precision both in research and in clinical 
work (153). In semi-structured interviews, the interviewer is allowed to use their own words 
or rephrase questions so the respondents can understand better.  
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The ECA study used the Diagnostic Interview Schedule (DIS) (154), but later studies have 
often used the Composite International Diagnostic Interview (CIDI) (155-158). Validity 
testing of diagnostic interviews often relies on acceptance of certain reference tests or 
procedures (e.g., ”gold standard” or “lead standard”) (159). Spitzer reviewed the 1980s 
diagnostic interviews and proposed the LEAD (Longitudinal Expert All Data) standard as a 
criterion measure (78;160;161). The LEAD standard deals with the need to do more than 
single examinations. Criterion diagnoses should be made by expert clinicians, and there 
should also be access to data from sources other than the patient to obtain the best possible 
quality of diagnoses.  
In clinical research, various standardized interviews are used, both structured and semi-
structured. A number of widely used diagnostic tools such as the CIDI (157), the Structured 
Clinical Interview for DSM-IV (SCID) (162;163) and the Mini International Neuropsychiatric 
Interview (MINI) (153;164) are also used for comorbid diagnoses (164;165). In clinical work, 
there is an increasing use of structured diagnostic interviews to complement clinical 
judgment. Some interviews need a clinician to make the diagnosis (e.g., the SCID); other 
interviews (e.g., the CIDI) can be used by non-clinicians following a structured training.  The 
instruments used in clinical settings form the basis of interventions and planning of treatment. 
Thus, these instruments should be as valid, reliable and feasible as possible. However, 
diagnosing comorbid disorders is particularly difficult since symptoms caused by abused 
substances may mimic symptoms of other mental disorders (3;166). The clinical challenge is 
then to differentiate between those disorders which are independent of substance use and 
those which are secondary to substance use.  The reliability of psychiatric diagnoses is 
reduced when psychoactive substance use is present (167-169). If a diagnosis is not reliable, it 
cannot be valid. Kranzler et al tested the SCID in substance abuse patients and found common 
comorbid disorders to have only moderate concurrent validity and poor predictive validity 
(170). The authors concluded that the diagnosis of comorbid mental disorders requires either 
additional expertise or the use of a diagnostic instrument specially designed for that purpose. 
Others have also found poor validity for psychiatric diagnoses in substance abusers (171). 
 Differentiation between independent and substance-induced mental disorders: Traditional 
diagnostic instruments rely mostly on the judgment of the clinician or the patient to 
differentiate independent disorders from substance-induced disorders (78;172). This may 
result in suboptimal diagnosis and treatment in this group of patients. The biological effects of 
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abused substances may independently cause psychiatric symptoms (3;76-78). In such cases, 
mental disorders might remit when subjects withdraw from substance use. Historically, the 
Feighner criteria distinguished between “primary” and “secondary” disorders according to the 
age of onset of each disorder (173). The Research Diagnostic Criteria (RDC), the DSM-III 
and the DSM-III-R used the categories “organic” and “non-organic” (174-176). However, 
specific guidelines for this differentiation were not provided and left the diagnostic process 
difficult since there was an increasing comorbidity of SUDs and mental disorders (78). Mark 
A. Schuckit, in the 1980s, suggested determining the independent disorder on the basis of the 
chronology of development of symptoms when alcoholism, anxiety and depression are 
concerned (177). According to the DSM-IV-TR nomenclature, there are three possible clinical 
presentations when subjects have co-occurring substance use and mental disorders. First, 
“independent disorders (=primary disorders)” are disorders which exist independently of 
substance use; however, these disorders might be complicated by SUD. Second, there are 
“substance-induced disorders” which have a causal connection with substance use. Third, 
there are the “expected effects” of the substances and these symptoms of intoxication and/or 
withdrawal should not be diagnosed as symptoms of a mental disorder (3). For example, 
according to the DSM-IV-TR criteria, a diagnosis of independent psychotic disorder in a 
patient with substance abuse requires “persistence of psychotic symptoms for a substantial 
period of time (i.e., a month or more) after the end of substance intoxication or acute 
substance withdrawal; the development of symptoms that are substantially in excess of what 
would be expected given the type or amount of the substance used or the duration of use; or a 
history of prior recurrent primary psychotic disorder” (3). Consequently, diagnosticians need 
to know the mental symptoms associated with the different classes of substances, and allow 
for assessments over time (76). The Psychiatric Research Interview for Substance and Mental 
Disorders (PRISM) was specifically designed to assess complex diagnoses in individuals with 
mental disorders who also abuse substances (178). 
 
1.5. Treatment issues   
Despite numerous studies on the high prevalence and deteriorating clinical course of mental 
disorders and co-occurring SUDs, advances in treatment have progressed slowly (179). 
Individuals with co-occurring disorders often remain untreated or undertreated (180-182). In 
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comorbid patients, psychoeducational approaches should motivate patients to reduce or stop 
their substance use to improve the clinical course of their other mental disorder (60;183). 
Studies have established the importance of integrating the treatment of patients with severe 
mental illness and co-occurring SUD to overcome the problems connected with care in 
separate systems (64;184-187). Further, findings from an integrated inpatient treatment 
programme showed that comorbid bipolar alcoholics and depressed alcoholics can be treated 
successfully, and benefits can last for up to two years (188). When studying data from five 
randomized controlled trials, it was concluded that it may be important to tailor interventions 
for dual diagnosis patients by substance type and type of mental disorder (86). A review 
showed group counselling, contingency management, and residential dual diagnosis treatment 
to have consistent positive effects on SUD in people with severe mental disorder (189). On 
the other hand, a Cochrane review (update 2007) found no compelling evidence to support 
any one psychosocial treatment over another to reduce substance use or to improve mental 
state in these comorbid patients (190). Methodological difficulties make interpretation of 
study results difficult. Further, existing guidelines concerning assessment and treatment of co-
occurring disorders need to be improved (191). A UK randomized controlled trial compared 
integrated motivational interviewing and cognitive behavioural therapy with standard care 
alone for people with psychosis and substance misuse (192). Unexpectedly, the intervention 
group did not have improved outcomes in terms of hospitalization, symptom outcomes, or 
functioning; however, the intervention group reduced the amount of substance used. These 
results might reflect the improvements in standard care for dual diagnosis patients during the 
last decade (192). Finally, in a study which compared patients with comorbid disorder from 
mental health settings with comorbid patients from drug treatment settings, only minimal 
differences emerged between the groups and none of the differences indicated a need for 
specialized treatments in separate systems of care (193). To sum up, the treatment of mental 
disorders complicated with SUDs seems to be dependent on the willingness to recognize the 
dual diagnosis challenge. Adequate treatment needs competence from both psychiatry and the 
substance abuse field, and clinical benefit is probably not dependent on rigorous 
organizational systems. 
 
1.6. Core areas: Research needs and clinically important questions  
Literature shows that the comorbidity of mental disorders and co-occurring SUDs is highly 
prevalent; further, comorbid disorders are disabling and often go untreated. There is a need 
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for comprehensive assessment and treatment of these comorbid disorders (18). Acute 
psychiatric wards in particular need both knowledge of the substance use among their patients 
and competence in examining these comorbid patients. In this thesis; exploring the prevalence 
of substance use problems in psychiatric inpatients and studying if patients’ self-report is 
confirmed by biological measures, is the focus of study I. In study II, the main focus is on 
improving the diagnostic methods since there is uncertainty when traditional methods are 
used in patients using substances.  
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2. Objectives 
This thesis consists of two studies carried out at Blakstad Psychiatric Hospital.  
Study I took place in 2001/2002 
The main objectives were: 
• To compare the results of toxicological substance screening at admission with 
patients’ self-reported recent substance intake. 
• To investigate prevalence of substance use problems among the younger psychotic 
patients admitted to the hospital from the catchment area in a specific time period.  
The specific research questions were: 
1) What is the concordance between self-reported recent substance use and toxicological 
screens in serum and urine (paper I)? 
2) What is the magnitude of substance use problems during the month prior to admission 
when measured by a standardized interview and toxicology screens (paper I)? 
3) What is the prevalence, the type and severity of SUDs using well-established and 
standardized methods in a group of psychotic patients admitted to a Norwegian 
psychiatric hospital (paper II)? 
 
Study II took place in 2007/2008 
The main objectives were: 
• To translate the Psychiatric Research Interview for Substance and Mental Disorders 
(PRISM) into Norwegian. 
• To test this first PRISM version on Norwegian patients in a psychiatric setting. 
• To investigate the comorbidity in a sample of inpatients with concurrent substance 
use. 
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• To investigate the diagnostic issue of independent versus substance-induced mental 
disorders. 
The specific research questions were: 
1) Is the PRISM feasible in an acute psychiatric ward (paper III)? 
2) What is the prevalence of different types of SUDs in different mental disorders (paper 
IV)? 
3) To what extent are mood disorders and psychotic disorders independent and/or 
substance-induced in patients admitted to the acute psychiatric ward with substance 
use (paper IV)? 
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3. Material 
3.1. Study samples 
Study I included 65 patients aged 17-40 years (born 1961 or later) consecutively admitted to 
Blakstad Hospital with psychotic symptoms in 2001. The median age of the included patients 
was 26.7 years (range=17.6 – 40.2 years) and 59% were men. Most patients were admitted to 
the acute psychiatric ward; only three patients were electively admitted to other inpatient 
wards in the hospital. Of the study patients 89 % had emergency admissions and 52% were 
involuntarily admitted. The median number of admissions, including the current 
hospitalization, was 2 (range = 1-25). In three of the 65 included patients the hospital stay was 
too short to complete all the study measures (these were excluded from paper II). 
To check for possible selection bias, at the end of the study period, the project leader went 
through all the admissions during the inclusion period of patients born 1961 or later. This was 
done through the patient administrative system CAPSY. Since the focus was to establish 
prevalence numbers of substance use problems among the patients, it might have been easy to 
overlook patients without substance use and “forget” to count them when the prevalence 
numbers were established. When scrutinizing the admission lists, no essential shortcomings 
were found.  
 
Study II included 61 patients aged 18-65 years consecutively admitted to the acute ward in 
Blakstad Hospital between November 2007 and December 2008 who presented mood 
symptoms, psychotic symptoms or both at admission. All the included patients had misused 
substances during the 30 days prior to admission according to the results of screening with the 
Alcohol Use Disorders Identification Test (AUDIT) and the Drug Use Disorders 
Identification Test (DUDIT). The median age of the included patients was 33 years (range 21 
– 59 years) and 71% were men. All included patients had emergency admissions, and 44% of 
study patients were involuntarily admitted. Median GAF function score was 38 (range 13-67). 
Median GAF symptom score was 40 (range 13-70). The median number of lifetime 
psychiatric admissions, including the current hospitalization, was 3 (range 1–33). In three of 
the 61 included patients the PRISM interview was not complete (these were excluded from 
paper IV).  
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Table 1 gives an overview of the two studies in relation to the four papers. 
 
Table 1. Number of patients included in the two studies and number of patients in the 
different papers. 
Study name Eligible patients  Included patients Paper I Paper II Paper III Paper IV 
Study I 77 65 (84%) 65 62   
Study II 119 61 (51%)   61 58 
 
 
3.2. Inclusion and exclusion criteria 
Study I: The basic inclusion criteria were positive psychotic symptoms reported in the 
referral, in the admission interview, or both – regardless of the existing information at 
admission on possible substance use problems.  In addition, we included patients with an 
already established diagnosis of psychotic disorder, regardless of symptoms at presentation. 
Only patients admitted directly to the hospital were included. In the inclusion period no other 
institution in the catchment area admitted this type of patients. Exclusion criteria were transfer 
from other hospitals (n=6), no knowledge of Scandinavian language or no knowledge of a 
European language known to the interviewers (n=2). 
Study II: Patients with possible or likely substance misuse were screened with the Alcohol 
Use Disorders Identification Test (AUDIT) and the Drug Use Disorders Identification Test 
(DUDIT). Male patients with an AUDIT score ≥ 8, female with an AUDIT score ≥ 6 and/or 
patients with DUDIT score ≥ 2 were invited to participate in a PRISM interview. Patients 
currently on opiate maintenance treatment (OMT) were asked to participate regardless of their 
current substance use. Exclusion criteria were insufficient knowledge of Norwegian or 
English, severe cognitive dysfunction, or patients being in sheltered environments during the 
whole previous month. That means we excluded patients admitted to other 24 hour care for 
the whole month before admission to the acute psychiatric ward and patients incarcerated in 
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the same period. Patients who met the inclusion criteria and who had been outside sheltered 
care for at least three days during the previous month were asked to participate. 
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4. Methods 
4.1. Study I - Laboratory analyses 
Urine and blood samples for toxicology screening were taken within 24 hours as part of the 
admission procedure. Urine sampling was observed by staff so patients could not manipulate 
the samples. The urine samples were screened for ethanol, barbiturates, benzodiazepines and 
benzodiazepine-like drugs, cannabis, carbamates, opioids, amphetamine and amphetamine-
like drugs, cocaine and hallucinogens. Blood was tested for the substance(s) found positive in 
the urine. We used liquid chromatography/mass spectrometry analysis (LC/MS), which was 
the most accurate screening method available for our study at that time (194).  
 
4.2. Study I - Standardized interviews 
The Addiction Severity Index (EuropASI version) (195) was used on all the included patients 
regardless of information of substance use beforehand. The ASI had previously been shown to 
be a generally reliable and valid assessment tool in dual diagnosis patients (196). The 
Norwegian version of the EuropASI has been found to be beneficial as an instrument for 
clinical use and for research purposes (197). We chose the EuropASI as a thorough measure 
for obtaining the patients’ possible current and lifetime substance use history. This 
multidimensional semi-structured interview examines problems and their severity in various 
areas of functioning. EuropASI consists of the following problem areas: medical status, 
employment and support status, drug/alcohol use, legal status, family history, family/social 
relationships, and psychiatric status. We excluded the medical status and the psychiatric status 
problem area from our ASI interviews, since we did not focus on medical status and did SCID 
interviews for psychiatric diagnoses. In each of the different problem areas a severity score, 
based on the evaluation from both patient and interviewer, is made. We recorded severity 
scores, but these scores are not published. We did not record composite scores. In the 
drug/alcohol use area, age of onset of substance use refers to the year the patient started using 
the substance at least three days a week (irrespective of dosage) or in “binges” for at least two 
consecutive days per week, i.e.to the point where substance use compromises normal 
activities. This criterion is repeated for each substance. The duration of substance use is 
counted as the number of years altogether where the relevant substances have been used in 
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this heavy way. The patient is also asked about use of substances during the preceding 30 
days.  In paper I, the EuropASI was used to investigate substance misuse during the 30 days 
prior to the current admission. In paper II the EuropASI was used only to investigate 
demographic data (living arrangements, marital status, educational status and employment 
status) and criminal record.  Data from other modules are not published.  
 
The Structured Clinical Interview for DSM-IV axis I disorders (SCID-I) was used to 
diagnose mental disorders (163). The SCID-I module A-D was used for acquiring the best 
possible diagnoses of patients’ psychotic disorders.  The different diagnoses of psychotic 
disorders possible to obtain from these modules are the following: mood disorders with 
psychotic symptoms, schizophrenia, schizophreniform disorder, schizoaffective disorder, 
delusional disorder, brief psychotic disorder, psychotic disorder due to a general medical 
condition, substance-induced psychotic disorder, and psychotic disorder not otherwise 
specified (NOS). When the ASI interview had revealed substance use, the SCID-I E module 
was added. This module diagnoses the substance abuse and dependence in the different 
substance classes; it also has a polydrug category.  We investigated lifetime and current 
(criteria present in the last month) SUDs.  
 
4.3. Study II - Screening of substance use 
Patients where there was suspicion of substance use were given the Alcohol Use Disorders 
Identification Test (AUDIT) and the Drug Use Disorders Identification Test (DUDIT) 
(132;198). This screening was mostly done the day after admission, but was delayed if 
patients had to be stabilized before completing the tests. A member of staff who was working 
with various screening procedures in the acute ward helped the first author identify the 
patients to be approached by the PRISM interviewers. These patients were asked to 
participate in the study on the basis of their AUDIT and DUDIT score. AUDIT and DUDIT 
are designed for self-administration by patients and, in our study, patients filled in their 
answers by themselves if they were capable of doing so. However, some patients were helped 
by the person in charge of the screening procedures.  
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4.4. Study II - Standardized interview  
The Psychiatric Research Interview for Substance and Mental Disorders (PRISM) is a 
semi-structured diagnostic interview specifically designed to assess complex diagnoses in 
individuals with mental disorders who abuse substances (178). The PRISM was developed at 
Columbia University in New York City in the 1990s to overcome the difficulties of 
distinguishing between independent and substance-induced mental disorders. PRISM follows 
the DSM-IV criteria and assesses 20 Axis I diagnoses (substance use disorders, mood 
disorders, psychotic disorders, anxiety disorders and eating disorders) and two Axis II 
diagnoses (antisocial and borderline personality disorder). The PRISM obtains a thorough 
history of heavy drug and alcohol use prior to other diagnostic sections. Unlike a number of 
other SUD assessments, the PRISM does not skip the dependence section when a subject does 
not meet the abuse criteria. The problem of missing SUDs when using abuse symptoms as a 
screen for a dependence diagnosis has been emphasized (146;148;149). The main purpose of 
the PRISM is to provide valid and reliable diagnosis of DSM-IV disorders by differentiating 
between the expected effects of intoxication and withdrawal, substance-induced disorders, 
and independent mental disorders. Specific guidelines throughout the interview aid in this 
differentiation. Substance-induced mood and psychotic disorders, as PRISM defines them, are 
rigorous diagnoses that require a full DSM-IV syndrome which exceeds the expected effects 
of intoxication or withdrawal. For instance, in the sections on depression, when the subject 
meets the symptom criteria but this coincides with an increase or decrease in substance use, 
this response is considered to be the expected effects of intoxication and/or withdrawal (199). 
On the other hand, when exploring a possible depressive episode during a period of steady-
state use of a relevant substance (i.e., a substance which might induce depressive symptoms), 
the specific depressive symptoms are explored further. In the psychosis section, when the 
subject is aware that their substance use has caused psychotic symptoms; e.g., hearing voices 
while high on stimulants and not acting on the voices, this psychotic symptom is coded as an 
expected effect of intoxication and does not count towards a diagnosis of psychotic disorder 
(199). Throughout the PRISM interview, there are numerous places in the probes where the 
subject’s own words or expressions are to be used whenever possible (“SOE”; subject’s own 
equivalent). For example, the subject’s own expression for being depressed (sad, blue, 
depressed, down etc.) is used when depression is the focus in the interview.  
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We chose the PRISM as the diagnostic interview because we wanted to differentiate between 
substance-induced mood and psychotic disorders and independent mood and psychotic 
disorders complicated with SUD.   We translated the PRISM from English into Norwegian 
according to the recommended guidelines (200-203). We used the development of the 
Spanish PRISM version as a model (204) and consulted the Head of the Drug Abuse Unit at 
Hospital del Mar, Barcelona. The PRISM interview (English, DSM-IV paper version) (205) 
was translated into Norwegian by a professional translation firm (Ganesa Tekst AS, Oslo, 
Norway). This first Norwegian version was reviewed by the first author in collaboration with 
clinical and research colleagues at the Norwegian Centre for Addiction Research, SERAF. 
Discussions were held to reach consensus on numerous words and expressions. Thereafter, 
the corrected Norwegian version was translated blindly into English (back translation) by an 
American psychologist fluent in written Norwegian (Deborah Lynn Reas, Oslo, Norway). The 
back translated version was then compared to the original version and discrepancies were 
corrected. The PRISM developers at Columbia University checked and approved the final 
back translated English version. The translation was a time consuming process since the paper 
version of the interview consists of approximately 80 000 words. 
Earlier studies of the English and Spanish versions of the PRISM have shown high reliability 
and validity for substance use disorders and other mental disorders in patient samples 
(178;204). However, the interview has, so far, mainly been used in research rather than daily 
clinical practice. The feasibility of using it in acute psychiatric wards has not been studied 
sufficiently.  
PRISM certification is based on participation in a 2-day workshop where an experienced 
PRISM interviewer evaluates a recorded interview submitted by the trainee.  Fortunately, a 
computer assisted version (PRISM-CV) is currently available and has been translated into 
Norwegian.  The PRISM-CV has the potential to be more user friendly in clinical settings, 
and beta testing to study this is underway.  
 
4.5. Ethical considerations 
Both studies were conducted in accordance with the declaration of Helsinki (206). Both 
studies were approved by the Regional Committee for Medical and Health Research Ethics 
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and the Norwegian Data Inspectorate. Patients gave their written consent after obtaining both 
oral and written study information. 
 In study I the Regional Committee of Ethics was asked to comment specifically on the ethical 
considerations concerned with including psychotic patients in the study. Psychotic patients 
might be disorganized to the extent that their ability to consent might be questionable. The 
committee answered that psychotic patients could be included even if their ability to consent 
might be questioned; however, patients must have understood the meaning of study. The 
committee concluded that professional judgment must be the basis for obtaining informed 
consent from the patients.  Research data on substance use among Norwegian psychiatric 
inpatients was scarce in 2001. The declaration of Helsinki states that, “populations that are 
underrepresented in medical research should be provided appropriate access to participation in 
research” (206). 
In study II, the clinicians in charge of the treatment signed declarations saying that patients 
were capable of giving a valid consent for participation. For each patient a summary report, 
based on the PRISM interview indicating substance use and diagnoses, was made. Most 
patients (84%) gave written consent to include this summary report in their medical record. In 
this way, patients and clinicians could benefit from the extensive information gained through 
the research interview.  
The payment from the Norwegian Centre for Addiction Research (300 NOK) given to 
patients after completing the PRISM interview, was accepted by the Regional Committee of 
Ethics. Nevertheless, the committee recommended that the circumstances around payment 
were considered carefully so as to avoid unnecessary pressure on patients to participate. The 
money given was regarded as a payment for the time patients spent participating in addiction 
research. We did not face difficult ethical considerations since almost all patients reacted 
positively to the interview and found it useful in improving their understanding of their own 
disorders.  
 
4.6 Statistical analyses 
Both studies were descriptive studies with the aim of exploring clinical issues. We did not aim 
at proving any specific hypothesis and did not do any power calculation of sample sizes 
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before starting the studies.  Both studies consisted of small clinical samples and therefore only 
simple statistical analyses have been performed. The Statistical Package for the Social 
Sciences (SPSS) version 11.0 and 16.0 respectively, was used for data analyses. In both 
studies SPSS was used for finding descriptive data on the included patients. In study I, 
Pearson’s chi-squared test was used for studying substance use with regard to demographic 
and other parameters. In study II, Pearson correlation coefficient was used for studying total 
PRISM interview time with regard to relevant parameters. Linear regression was used to 
study the relation of total PRISM interview time to the number of non-SUD psychiatric 
diagnoses, number of SUDs, and to the DUDIT score. 
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5. Results  
Self-report of substance use versus toxicology screens 
In 63 of the 65 patients (97%), we found agreement between self-reported recent substance 
intake and the findings in the toxicological screens (paper I). Included in this number are 11 
patients (17%) where their toxicology screens were negative on illegal substances which the 
patients reported having used during the month prior to admission. Only one patient had a 
positive substance screen for a drug of abuse not reported in interview.  
 
Prevalence and pattern of substance use in the patient sample 
Thirty-five patients (54%) reported having used one or more substances for intoxication 
during the month prior to admission (paper I). Of these, 26 patients (40% of total study group) 
had used illegal drugs, while nine patients (14% of total study group) had used only alcohol 
for intoxication. Laboratory analyses revealed use of illegal drugs, mostly cannabis and 
amphetamine, in 22 patients (34%). Benzodiazepines were found in 27 of 65 laboratory tests. 
In only two of these tests the benzodiazepine level was above the therapeutic level. We did 
not find any difference in current substance use between voluntarily admitted patients and 
those admitted involuntarily. There was a tendency towards more substance use among men 
than women.  
Sixty patients had complete SCID-I assessments for diagnosing current and lifetime SUDs 
and current psychotic disorders (paper II). The lifetime rate of SUDs was 70% when all 
psychotic disorders were included and 62.5% when substance-induced psychotic disorders 
were excluded. Fifty percent of all the patients studied had current SUDs. In the patients with 
independent psychotic disorders and co-occurring SUDs, two-thirds had lifetime substance 
dependence diagnoses, while one third had lifetime abuse diagnoses without meeting the 
dependence criteria.  Alcohol, amphetamine and cannabis were the substances most 
frequently found in the dependence disorders. Ten patients (16.7%) had more than one illegal 
substance involved in their SUDs. None of the patients had benzodiazepine use disorders 
without the abuse of, or dependence on, other substances. The dominant pattern was the use 
of illegal substances. 
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Feasibility of the PRISM  
Sixty-one of the 119 eligible patients (51%) were included for feasibility measures (paper III). 
The main reasons for non-inclusion among eligible patients were too short a stay in hospital 
(n=29) or refusal (n=13). A complete PRISM interview was obtained from 58 of the 61 
patients. Median total interview time was 155 minutes. The median number of interview 
sessions per patient was three. The median time from admission to start of interview was nine 
days.  The median time from first to final interview session was four days. According to the 
AUDIT and DUDIT scores, 21 patients (34%) misused alcohol only, 17 patients (28%) 
misused drugs alone and 23 patients (38%) misused both alcohol and drugs.  
Total interview time was related to the DUDIT score, the number of substances misused the 
number of SUDs, and the number of non-SUD psychiatric diagnoses.  The interviewers noted 
very few problems when conducting the interviews. Patients mainly had positive reactions to 
the extensive PRISM interview.  
 
Types of SUDs.  Independent or substance-induced disorders 
Patients had extensive and long-standing substance use (paper IV). The substances most often 
heavily used were alcohol (71%), cannabis (52%) and stimulants (38%). Cannabis had the 
earliest median age of onset of heavy use (age 17); the median age of onset of heavy use for 
all other substances was age 22. 
 
The four most common current diagnoses were major depressive episode (MDE) (50%), 
schizophrenia (21%), manic episode (10%), and mood disorder with psychotic symptoms 
(9%) (paper IV). Forty percent of the participants had current substance-induced mood or 
psychotic disorders. Substance use seemed particularly important in relation to current 
depression. The large majority of diagnosed current MDEs were substance-induced (21/29; 
72%), and over one third (36%) of all study participants received a current substance-induced 
MDE diagnosis. In the current substance-induced MDEs, 57% were alcohol-induced. 
 
Current psychotic disorders were less often substance-induced. Current schizophrenia was 
independent of substance use in 11 of the 12 patients who received a schizophrenia diagnosis. 
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In one patient, schizophrenia was cannabis-induced. Non-schizophrenia psychotic disorders 
were substance-induced in five of seven patients. 
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6. Discussion 
6.1. Discussion of main results 
Self-report of substance use versus toxicology screens 
We found patients admitted with psychotic symptoms to be reliable in reporting their 
substance use during the last month before admission (97% concordance between self-
reported recent substance intake and the findings in the toxicological screens). Seventeen 
percent of patients had negative toxicology screening even if these patients had reported 
illegal substance use during the previous month.  This comes naturally from the different time 
frames; the EuropASI measured self-reported substance use during the previous 30 days, 
whereas the toxicology screening we used might detect substances in urine roughly 2-7 days 
after intake. Earlier studies in this patient group had found somewhat conflicting results when 
comparing self-report with toxicology screening. In an American study of psychotic patients 
only 21% of those with positive urine test self-reported substance use (207). In another 
American study where the utility of drug screening in an urban psychiatric emergency service 
was studied, 88% of those who admitted use had positive drug screens (208). In a Swiss study 
of psychiatric inpatients, good agreement was found between self-reported substance use and 
urine screens (23). Other authors also found relatively high concordance rates between self-
report and urine screens in people with co-occurring mental disorders and SUD (209).  
Literature has also shown that self-reports of substance use are valid and reliable among both 
injecting drug users (210) and university students (211). Australian researchers have recently 
published a meta-analysis of self-reported substance use compared with laboratory substance 
assay in various psychiatric services (212). Our study findings are included in that meta-
analysis. They found a strong association between self-report of any substance use and a 
positive substance screen for any substance. Unexpectedly, they found a stronger association 
between self-report and testing in studies with a higher proportion of patients diagnosed with 
psychotic disorder. They also found that the studies using a structured interview to assess 
substance use reported a significantly stronger association between any reported substance 
use and substance screening than did the studies assessing substance use using clinical 
methods. Furthermore, they presumed that the false negative tests (low sensitivity) are the 
main limitation of testing. This can be due to the lack of sensitivity of the substance assays 
and/or the time lag between substance intake and sampling (212).   
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In conclusion, our study showed that we can rely on self-reported substance use in psychotic 
inpatients. However, at the time of the interview, patients knew that toxicology screens were 
taken and that they were promised confidentiality. These issues probably increased the levels 
of agreement. Therefore; if patients feel safe and there is absence of sanctions, one might 
expect quite accurate substance use reports. Then there is less need for the toxicology screens. 
 
 Prevalence and pattern of substance use in the patient sample 
We found that about half of psychotic inpatients had intoxicated themselves on various 
substances during the month prior to admission. The substances most commonly used in our 
survey were alcohol, cannabis and amphetamine.  The prevalence of both current and lifetime 
SUDs was high in the patient sample. The lifetime rate of SUDs was 70% when all psychotic 
disorders were included, 62.5% when substance-induced psychotic disorders were excluded. 
We also found a high prevalence of current SUDs (50%). The relevance of our finding is also 
reflected in the fact that half of the current SUDs were dependence disorders. For lifetime 
SUDs the relevance is further strengthened, as the majority of these were dependence 
disorders. 10-year data from the New Hampshire Dual Diagnosis Study showed that 
participants with alcohol dependence rather than alcohol abuse were less likely to attain 6-
month remissions and more likely to relapse after attaining remissions (213). This emphasizes 
the importance of establishing interventions in psychiatric services aiming at preventing 
substance use from developing into substance dependence.  
Other Norwegian studies have also found SUDs to be prevalent in psychiatric inpatients. 
However, these patient samples also include patients other than psychosis patients. Fløvig et 
al found that acute psychiatric patients had used substances prior to admission in 82% of the 
admissions, and almost one-third of patients had a SUD (27). Mordal et al found in their acute 
psychiatry study that psychoactive substances were detected by laboratory analyses in 63% of 
the admissions (28). On the other hand, findings from a Swedish clinical psychosis unit 
showed much lower prevalence of SUDs than in our study: 18% harmful alcohol use and 9% 
drug-related problems (214).  However, studies from numerous clinical settings have shown 
high prevalence numbers of substance use in patients with psychotic disorders (33-40). 
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Both toxicology screens and interviews revealed cannabis and amphetamine to be the most 
frequently abused illegal substances in psychotic inpatients.  This is in accordance with other 
findings (33;36;214). A Swedish study has shown that the distribution of psychotic illness is 
high among abusers of amphetamine and cannabis, in contrast to the generally lower co-
occurrence of psychosis among abusers of opiates (215). The fact that stimulants might 
induce psychotic disorders has been known for a long time (89;216;217). Further, studies 
have linked cannabis use to the development of schizophrenia and other psychotic disorders 
(92-96;127;128;218), and studies have suggested that cannabis use precipitates psychotic 
disorder in subjects who are vulnerable to developing psychosis (219;220). Also, a large 
cross-sectional analysis has found a dose-response relationship between the amount of 
cannabis used and the odds of psychiatric hospitalization (221). Early age cannabis use 
increased the odds. A Danish follow-up register study found that half of all patients treated for 
cannabis-induced psychosis will subsequently develop a schizophrenia-spectrum disorder 
(222). A review of 35 studies found evidence consistent with the view that cannabis increases 
risk of psychotic outcomes independently of confounding and transient intoxication effects 
(223). 
We found that it was difficult to compare our prevalence findings to other European countries 
because of methodological differences. Our study focuses on the age group 18–40 years.  As 
substance use disorders are associated with younger age (33;36;37;118;224-226), the age 
selection is likely to cause a higher prevalence than found in studies that include older age 
groups.  
 
The high level of comorbidity is not easily explained by the substance use pattern in Norway. 
The patients in this study have a different pattern of use from the general population; illegal 
substances dominate patients’ substance use while alcohol problems are the main problem in 
the general population (227). The pattern of substance use found in our study might also be 
influenced by the tendency of psychiatric services to refuse subjects with alcohol use 
disorders – at least at the time when study I was conducted. Anyway, as found by others, 
patients with schizophrenia have greater problems with substance use than the general 
population (228;229). Another noteworthy finding is that our prevalence numbers are similar 
to findings in US clinical studies (36;224), even if drug use disorders are more prevalent in 
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the US than in Norway (5). One explanation might be that the public health care system in 
Norway facilitates easier access to inpatient psychiatric care compared to other countries.  
 
Our prevalence numbers are naturally a reflection of the 2001 organization of Blakstad 
hospital catchment area. In later years, more differentiated services have been established and 
more focus has been put on establishing better services for dual diagnosis patients. Probably, 
if a corresponding survey had been carried out in 2012 in the acute ward, prevalence numbers 
would have been somewhat lower. However, the prevalence numbers in the 2001 survey 
should reflect the real situation at that time since our findings resulted from a thorough 
sampling procedure and an in-depth inquiry into substance use.  
 
In conclusion, the high prevalence and severity of SUDs found among psychotic inpatients, 
compared to the general population, are crucial findings for the planning of treatment. A high 
prevalence of current SUDs poses great challenges for the planning of further follow-up.  We 
found substance use to be prevalent in an acute psychiatric ward. Studies from emergency 
departments have shown that these departments are important identification sites and should 
serve as important venues for cost-effective interventions (230-232).  
 
Feasibility of the PRISM  
An overriding research question in study II was to investigate a diagnostic method for use in 
dual diagnosis patients in a busy clinical setting. This study demonstrated that it was feasible 
to use PRISM in a busy acute psychiatric ward with a relatively high percentage of 
involuntary admissions.  This is important because the feasibility of any complex diagnostic 
interview in everyday clinical work is questionable. We succeeded in doing PRISM in half of 
the eligible patients. The main reason for non-inclusion was too short a stay on the ward, 
which meant there was not enough time to stabilize the patients and establish the patient –
interviewer alliance. We found that the amount of drug use and increasing psychiatric 
morbidity lengthened the interview. Others have also found that complicated substance use 
and psychiatric histories lengthen administration times (157;205). 
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As shown both in spontaneous comments and in interviewer observations, the patients seemed 
to appreciate the thoroughness of the examination. Some even expressed increased 
understanding of how substance use interfered with their mental health problems. Patients 
appreciated the structured way the PRISM interview made them recall their history of 
substance use and mental disorders. They expressed satisfaction about being diagnosed so 
thoroughly. The same kinds of experiences were confirmed in another Norwegian PRISM 
study (233). Furthermore, patients’ satisfaction motivates investigators to carry out further 
psychiatric research.  
The feasibility of the PRISM interview has been questioned because of its extensive and time-
consuming nature. The Columbia group had a mean administration time of 2.03 hours when 
excluding the first five interviews done by each interviewer (205). In our study the PRISM 
interview was indeed time-consuming, with a median interview time of 2 hours 35 minutes. 
This is, however, comparable to the CIDI interview which in some studies has been described 
as taking up to two to three hours, with the substance use disorder section being especially 
time-consuming (156). The SCID interview has been shown to take less time, but this was 
found in a community mental health setting (234). However, as reviewed in the methodology 
section in this thesis, other diagnostic interviews have shortcomings when used in subjects 
who abuse substances. Thus, the PRISM interview may have advantages over these other 
diagnostic options. Shorter diagnostic instruments like the MINI have been developed, but 
will naturally give less information because of the shorter format (153;235). Studies have also 
shown that even the MINI interview has many of the same problems that we encountered with 
the PRISM interview; it is not feasible for all patients because of short stays on the ward, 
involuntary admissions, psychosis, and substance use (164). In conclusion; proper diagnosis 
of comorbid patients takes time. Earlier studies have shown that structured interviews 
enhance diagnostic accuracy, and diagnostic precision leads to cost-effective practices and 
better patient care (234;236).  
 
Types of SUDs: In our combined psychotic and mood-disordered patients in study II; alcohol, 
cannabis and stimulants were the substances most often heavily used and associated with 
current SUDs. This pattern of substance use is in accordance to several other studies 
investigating substance use in psychiatric inpatients (25;27;33;36;214). The higher rates of 
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cocaine use reported in some studies is probably due to geographical drug preferences and 
availability. PRISM should give a reliable measure of all possible SUDs in the subjects 
interviewed since the PRISM diagnoses abuse and dependence independently (178).  
 
Independent or substance-induced mental disorders: The PRISM revealed that the majority 
of current MDEs were substance-induced, and current psychotic disorders were substance-
induced in about one third of the patients with a psychosis diagnosis. We found that alcohol 
plays an important role in acutely admitted patients with MDE. This comorbidity is supported 
by clinical, epidemiological, and neurobiological research which suggests an association and 
causal relationship between alcohol and depression (30;79;80;237;238). This association is 
complex (30;237;239). It has been shown that remission of alcoholism increases the remission 
of depression (240;241). Findings from a community study supported a causal model in which 
problems with alcohol led to increased risk of major depression (242). Another 
epidemiological survey found prior alcohol dependence to increase the risk of current major 
depressive disorder more than 4-fold (243). Concerning the other possible direction of this 
specific comorbidity, a prospective study demonstrated a modest role for independent 
depressive episodes in enhancing the risk for alcohol problems (62). Data from the 
Collaborative Study on the Genetics of Alcoholism was used to study independent and 
substance-induced major depressive disorders in alcoholics (244). Here, the majority of 
depressive disorders were substance-induced. A clinical study found that in substance-
dependent patients both independent and substance-induced major depressive disorder 
predicted future depression (245). Furthermore, a previous clinical study concluded that 
substance-dependent patients with both independent and substance-induced MDEs have 
greater psychiatric severity than those with independent MDE only or substance-induced 
MDE only (246). A recent NESARC publication suggests that substance-induced depression 
and major depression with comorbid SUD may share underlying etiological factors since 
these conditions show similar patterns of comorbidity and risk factors (247).  
In our study, past MDEs were most often independent, while current MDEs were mainly 
substance-induced. This is in accordance with a recent Norwegian study of mental disorders 
in first-time admitted SUD patients diagnosed with the PRISM (233). In that study, 69 percent 
of the patients with mood disorder had experienced one or more lifetime independent mood 
disorder episodes. Also, studies of clinical populations have shown that 25 to nearly 40% of 
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carefully diagnosed substance-induced MDEs assessed at baseline are later recategorized as 
independent depressive episodes (245;248). Knowledge of the patient’s current and previous 
symptoms and disorders may be helpful in guiding the diagnostic process (249). Diagnosing 
patients with active SUDs and mood instability is challenging, bipolar disorders might be 
overdiagnosed (250). Conversely, a study found that bipolar disorder had not been previously 
diagnosed in approximately 50% of males admitted to an inpatient substance abuse 
programme (251). The PRISM does not have bipolar disorder as a distinct diagnostic 
category. However, from investigating various mood episodes, information about possible 
bipolar disorder might be obtained. To sum up, accurate assessments of depressive symptoms 
complicated with SUD seem necessary to give optimal treatment for both the depressive 
disorder and the SUD. Psychoeducative approaches seem warranted in these patients.  
Most cases in the total group of current psychotic disorders were classified as independent. 
We found that schizophrenia, the most prevalent current psychotic disorder, was rarely 
substance-induced, while current non-schizophrenia psychotic disorders were mostly 
substance-induced. When making differential diagnoses in psychotic patients who abuse 
substances, it is important to establish the temporal relationship between substance use and 
psychotic symptoms (91). In clinical practice, a diagnosis of substance-induced psychosis is 
often given shortly after admission (252). This could deflect the clinical focus away from a 
current independent psychotic disorder. A longitudinal study of participants with early-phase 
psychosis from five psychiatric emergency departments in upper Manhattan used the PRISM 
for assessments (253). In this study, 56% of the psychotic disorders were diagnosed as 
independent at baseline. Further, the investigators identified three key predictors as being 
greater in the substance-induced group: parental substance abuse, a diagnosis of dependence 
on any drug, and visual hallucinations (253). However, they also demonstrated that as many 
as 25% of patients with baseline substance-induced psychosis were reclassified as having 
independent psychosis at one year follow-up (254). Consequently, even with thorough 
diagnostic assessment at one point in time, diagnoses might change over time. Substance 
abuse and noncompliance with medication regimens has been associated with higher relapse 
and hospitalization (87). Patients with substance-induced psychotic disorders and patients 
with co-occurring independent psychotic disorder and SUD should receive integrated 
treatment that includes psychoeducation and motivational techniques to address substance 
abuse and to improve the clinical course of both disorders (60;183).  
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The distribution of independent and substance-induced psychotic disorders in this study may 
also be influenced by the types of drugs abused in the study catchment area. In populations 
from catchment areas with higher rates of cocaine and stimulant use, we would expect more 
substance-induced psychosis than independent psychosis. Also, the organization of patient 
flow to psychiatric and substance abuse treatment systems may influence the rates of 
independent versus substance-induced psychotic disorder in acute psychiatric units. The level 
of severity of mental disorder managed in a substance abuse service will naturally depend on 
the psychiatric competence in that specific service.  
 
In conclusion, we showed that it was possible to distinguish between independent and 
substance-induced mood and psychotic disorders in patients admitted to an acute psychiatric 
ward. This distinction has important consequences for the further treatment and follow-up of 
patients. Optimal treatment needs optimal diagnostics. Discussing disorder mechanisms in 
more detail and in a more personalized way with patients probably enhances the chance of 
initiating motivation for substance use reduction.  
 
6.2. Methodological considerations 
Toxicology screening 
Toxicology screening was only used in study I. We used liquid chromatography/mass 
spectrometry analysis (LC/MS). A more recent Norwegian study compared urine on-site 
drugs of abuse screening test with LC/MS analyses in patients admitted to a psychiatric 
emergency unit (255). This study used the Department of Clinical Pharmacology at St.Olav 
University Hospital for the LC/MS analyses, as we did. Here, 75% of on-site tests were 
correct for the drug tested when compared to the chromatographic analyses, and the authors 
concluded that results from on-site screening tests should not be considered as the final 
conclusion. Therefore; our choice of toxicology screening method should give as accurate as 
possible results for patients’ recent substance intake. Chromatographic analyses are 
subsequently supported as a routine screening which should be considered in acutely admitted 
psychiatric patients (256). Roughly, substances might be detected in urine 2-7 days after 
intake with the LC/MS method we used. Consequently, substances used during the last month 
before admission, can be missed. Our results confirmed this fact; more patients reported 
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substance use during the last month than the substance screening showed.  If valid 
information about substance use over a longer time period had been wanted, hair analyses 
could have been used (257-259). However, this method was not available for our study. Nor 
was it necessary, since our main screening focus was to study the very recent substance use in 
psychotic inpatients.  
 
 Substance use screening instruments 
In study II, we used the AUDIT and DUDIT as screening instruments to identify relevant 
patients to be interviewed with the PRISM. We decided to set the AUDIT cut-off at 8 for men 
and at 6 for women. This is a frequently used cut-off. A cut-off of 8 provides good sensitivity 
and specificity in the detection of current social and medical problems related to alcohol (260) 
and produced the highest level of correct classification in the schizophrenia sample (135). 
Women are more susceptible to the medical complications of alcohol. Therefore we chose an 
AUDIT cut-off at 6 for the female patients.  This cut-off has previously been shown to be the 
most useful cut-off for detecting alcohol problems in a group of Spanish women (261). We 
decided to use a DUDIT cut-off at 2 for both genders since we wanted to reach all patients 
who may have substance-related psychiatric symptoms. In patients with schizophrenia/SMI, 
even lower levels of substance use might cause negative effects (84;262). Nesvåg et al 
concluded in their investigation in patients with first-episode psychosis that suitable cut-off 
scores were ten for men and eight for women on AUDIT and three for men and one for 
women on DUDIT (263). 
 
Standardized interviews 
EuropASI: The reliability and validity of the ASI in severely mentally ill patients have been 
questioned (264), and it has been stated that interviewers should have some clinical 
experience with psychiatric patients prior to conducting ASI interviews (265). In our study the 
ASI interviews were conducted by experienced clinicians (VH and TLE). An earlier study has 
shown that the ASI missed approximately 20% of SCID-positive psychoactive SUDs, but that 
the specificity was 95% to 98% (266). Findings from another study supported the use of the 
ASI drug and alcohol scales in public psychiatric hospitals (267).  
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We encountered problems with the severity scores in some of the problem areas. Many 
patients were unemployed and lived on disability benefits; consequently, judging problems 
with work was often irrelevant. Legal problems were also often irrelevant since patients’ 
criminal cases were often dropped because of their severe mental illness. Problems with 
family and others might be misunderstood because of conflicts and paranoid symptoms. 
However, these assessments were not used in the publications from the study. We did not 
encounter any particular problems with the alcohol and drug section. Obviously some patients 
in this study group had problems remembering their substance use history because of 
cognitive impairment both from longstanding psychotic disorder (268) and longstanding 
substance misuse. However; patients’ self-reported substance use during the previous 30 days 
as obtained by the ASI interview, was compared to the toxicology screening. Since the urine 
toxicology screens confirmed patients’ self-report, the ASI seemed to be a reasonable method 
to get detailed information of current substance use even in psychotic inpatients. In another 
study ASI was used under naturalistic conditions and clients did not underreport their 
substance use when ASI information was compared with urinalysis (269). Further, a recent 
publication supports the use of ASI in clinical practice and research (270). In conclusion; we 
found the substance module in the ASI to be a good tool in finding the best estimate of current 
substance use in a group of psychotic patients.  
SCID-I: The SCID- I module E complemented the ASI substance use history. Our ASI and 
SCID findings were in agreement: through the ASI interview we found that 54% of the total 
65 patients had used substances to intoxication during the last month. In the 60 patients with 
complete assessments we found 50% to meet criteria for substance abuse or dependence the 
last month before admission.  
Study I was primarily aimed at examining substance use and SUDs in a group of psychotic 
inpatients. All patients were interviewed with the ASI interview, including the drug/alcohol 
section, before the SCID-I interview. Patients knew that toxicology screens had been taken 
before they were interviewed. Thus, multiple methods of assessment of substance use in 
psychiatric patients were used, as often recommended (139;140;207;226;271). A previous 
study found that urine toxicology analyses supplemented with admission and discharge 
diagnoses were significantly less accurate in diagnosing psychoactive substance abuse than 
the SCID (272). Structured methods are found to be significantly better than unstructured 
traditional diagnostic assessment (236), combining structured interviewing with a review of 
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the medical record appears to produce more accurate diagnoses than routine clinical methods 
(234), and good diagnoses require clinical skills (273). In our prevalence study, both SCID 
interviewers were experienced clinicians. The conclusions of these other publications 
strengthen the credibility of our prevalence findings.  
The problems with the validity and reliability of structured interviews when subjects abuse 
substances have been reviewed in the methodology section in this thesis (167-170). In study I, 
the types of psychotic disorders were subordinate to the prevalence question. However, our 
SCID-I experience was that the differentiation between an independent psychosis diagnosis 
and a substance-induced psychosis diagnosis had to, at least to some extent, be based on 
clinical judgment. These considerations point toward the necessity of using a diagnostic 
interview specifically designed to assess complex diagnoses in individuals with mental 
disorders who abuse substances. The Psychiatric Research Interview for Substance and 
Mental Disorders (PRISM) was developed for this purpose (178).  
PRISM: Clinical interviews often yield inaccurate diagnosis when patients have co-occurring 
disorders (236;274); and the reliability and validity of psychiatric diagnoses is reduced when 
psychoactive substance use is present, even if structured interviews are used (167-171). 
Consequently, there is a need to improve diagnostic accuracy in clinical settings with 
instruments designed to disentangle the complex interactions between substance use and 
mental disorders. We wanted to find valid and reliable diagnoses in acutely admitted dual 
diagnosis patients; PRISM was therefore chosen as the diagnostic instrument in study II. 
Earlier studies of the English and Spanish versions of the PRISM had shown high reliability 
and validity for substance use disorders and other mental disorders in patient samples 
(178;204;205). Our results are also strengthened by the fact that all interviews were done by 
experienced clinicians; clinical skills ensure valid data when using structured diagnostic 
interviews (273). 
With some of the polydrug users it seemed at first impossible to disentangle all their 
substance use in the thorough way that PRISM requires.  However, when we were writing up 
the summary reports for the patients’ medical records, things gradually fell into an order. This 
writing up also facilitated our learning process considerably.  
We had translated the PRISM into Norwegian with a thorough process. Obviously, the 
validity of a translated diagnostic interview is dependent on a proper translation process. 
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Further, the reliability will be low if the diagnostic questions are not consistent and optimal in 
their linguistics. Besides, if the questions are difficult to grasp for the patients, the use of 
structured interviews might be misleading and a waste of time. Our translation was done in a 
professional milieu with both clinical and research knowledge in addiction medicine and 
psychiatry. However, there should always be cross-cultural considerations concerning the 
validity of translated research instruments (203;275). 
 
6.3. Limitations 
In both study I and II, the small sample sizes and single setting raises questions regarding 
statistical significance and generalizability. In study I; the demographic characteristics of the 
catchment area, the substance use pattern in the catchment area, and the current local 
organization of psychiatric services played an important part in the prevalence numbers 
obtained. In study II, local characteristics also influenced the findings. However, both studies 
were “real world” studies which naturally limited the generalizability.  
Study II was cross sectional and therefore it was not possible to investigate clinical benefits of 
structured diagnostic assessment in acute psychiatric inpatients. Moreover, there was no 
follow-up on the diagnoses in the PRISM study. Since diagnoses might be reclassified over 
time, a diagnostic follow-up would have given a broader understanding of the patient sample. 
We naturally encountered some difficulties performing the PRISM interview. Some psychotic 
patients experience cognitive deficits (268) or psychotic symptoms that render it difficult to 
recall previous specific illness episodes. Previous psychotic episodes reported by the patients 
were therefore verified by checking medical records to identify past psychiatric 
hospitalization. It was challenging trying to ascertain whether patients had been abstinent for 
at least four weeks when they had their previous psychotic symptoms. Antipsychotic 
medication during this time period complicated the differentiating of independent versus 
substance-induced psychotic disorders. Because episodes of mood disturbance do not always 
result in hospitalization, it was not possible to conduct similar validity checks for mood 
disorders.  Further, there may always be recall bias concerning past symptoms.  
Our PRISM findings will naturally have some limitations as far as diagnostics in acute 
psychiatric wards are regarded. The median time from admission to start of interview in this 
51	  
	  
study was nine days (range 1 – 55). Consequently, it was difficult to carry out the interview in 
short stay patients. All but two patients required more than one session on different days to 
complete the PRISM interview. 
Our findings should be understood in the light of current developments in diagnostic 
understanding.  The PRISM follows the DSM-IV criteria to distinguish between independent 
and substance-induced disorders, and the PRISM emphasizes the temporal relationship 
between substance use and mental symptoms. The DSM-IV criteria for substance-induced 
psychotic disorder have been questioned, and an alternative classification reflecting 
association with substance use rather than causation has been proposed (276). In a literature 
review for the years 1992 through 2007, the authors concluded that there has been a striking 
paucity of information concerning substance-associated psychotic episodes (276). Future 
research will certainly need to consider these diagnostic issues. An earlier literature review 
recommended that DSM-V should retain the independent and substance-induced categories 
but that the criteria should be refined since the DSM-IV leaves much of this differentiation to 
clinical judgment (277).  However; in the PRISM, as opposed to the SCID-I, there are specific 
guidelines which try to elaborate and refine these independent/substance-induced diagnostic 
challenges.  
 
6.4. Clinical implications and future research 
Our study revealed a high prevalence of SUDs among psychotic inpatients. Both the current 
and lifetime prevalence of SUDs were high in this group of patients. This means that 
psychiatric services should be aware of this comorbidity from a patient’s first contact with the 
treatment systems. There is no doubt that persistent SUD deteriorates the clinical course of 
psychotic disorders. Future research should further investigate methods for optimal detection 
of SUDs in subjects with mental disorders. A recent meta-analysis searched publications 
reporting data about the characteristics of current and former substance-using patients 
diagnosed with psychotic illness (278). The authors found significant improvements in 
symptoms among patients with first episode of psychosis who stopped using substances, 
while these improvements were not found in patients with a more established psychotic 
disorder. Hence, first episode patients should be informed about the benefits of giving up their 
substance use (278). Clinical experience has shown that it is often difficult to intervene when 
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the SUDs have persisted too long in psychotic patients. Psychiatric services should have 
proper screening and diagnostic guidelines for this comorbidity in order to give proper 
information and treatment options to the affected patients in due time.  
We have shown that it was possible to use an extensive diagnostic interview in psychiatric 
inpatients with co-occurring SUDs. In addition to obtaining the substance use history and the 
various psychiatric diagnoses, the PRISM interview can also be regarded as a therapeutic 
intervention for the patients. Structured interviews might start patients’ own reflections 
regarding their substance use. Awareness and reflection are first steps in initiating change. For 
clinicians, carrying out structured interviews like the PRISM facilitates consideration about 
what the important questions are. This knowledge can later be transferred into clinical 
consultations. 
The PRISM interview provided detailed, clinically significant information on diagnoses in 
patients hospitalized for acute mental disorder with concurrent substance use. The high 
prevalence of current substance-induced depressive states indicates that targeted treatment for 
SUDs is particularly important for these patients. Further, an earlier prospective longitudinal 
study of people with both major depressive disorders and alcoholism suggested that “the 
beneficial effect of abstinence operates regardless of when it starts; it is never too late to 
benefit from achieving inactive alcoholism” (240).  Current psychotic disorders were mostly 
independent. When mental disorder is independent, proper psychiatric treatment is important 
and should be integrated with substance abuse treatment to sustain recovery.  
Future research should further explore methods to obtain the best possible diagnoses in 
subjects with mental disorders and SUDs since the diagnoses are the basis of treatment 
planning. Diagnostic accuracy in psychiatric services is important for targeted treatment. The 
Norwegian computer version of PRISM is currently undergoing pilot testing. This version has 
the potential to be more user friendly in clinical settings than the paper-and-pencil version we 
used in our study.  
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7. Conclusions 
The main results in this thesis can be summarized in the following points: 
• Examination through the EuropASI and the SCID-I interview showed that substance 
use and substance use disorders were highly prevalent in psychotic patients admitted 
to inpatient psychiatric care. Alcohol, amphetamine and cannabis were the dominant 
substances. 
• Fifty percent of the psychotic patients had current SUDs. Lifetime rate of SUDs was 
70% when all psychotic disorders were included and 62.5% when substance-induced 
psychotic disorders were excluded.  
• Urine toxicology screens confirmed patients’ self-report of recent substance use.  
• The first Norwegian version of the Psychiatric Research Interview for Substance and 
Mental Disorders (PRISM) was tested in substance-abusing psychotic and mood 
disordered patients admitted to an acute psychiatric ward. The PRISM was feasible in 
this setting, and patients mainly had positive reactions to this extensive interview.  
• Median total PRISM interview time was 155 minutes. The interview time was 
statistically related to the DUDIT score, the number of substances misused, the 
number of SUDs, and the number of non-SUD psychiatric diagnoses.  
• The PRISM revealed that 40% of patients had current substance-induced mood or 
psychotic disorders. Current major depressive episode was substance-induced in 72% 
of patients with this diagnosis, of which 57% were alcohol-induced. Current psychotic 
disorders were substance-induced in about one third of the patients with a psychosis 
diagnosis. These substance-induced psychotic disorders were mainly induced by 
illegal substances.  
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 9. Appendices 
 
Informasjon	  til	  vakthavende	  lege	  og	  akuttavdelingene	  angående	  prosjektet	  
Forløpsstudie	  av	  alkohol,	  medikament-­‐og	  narkotikamisbruk	  hos	  innlagte	  
pasienter	  med	  psykosediagnose	  
	  
Fra	  og	  med	  3.mai	  01	  gjennomføres	  en	  grundigere	  kartlegging	  av	  evt.	  
rusmisbruk	  hos	  en	  gruppe	  innlagte	  pasienter.	  Alle	  pasienter	  i	  alder	  16-­‐40	  år	  
(d.v.s.	  født	  1961	  og	  senere)	  som	  innlegges	  med	  psykosediagnose	  får	  
forespørsel	  om	  å	  delta	  i	  studien,	  helt	  uavhengig	  om	  det	  er	  mistanke	  om	  
rusmisbruk	  eller	  ikke.	  Prosjektleder	  oppsøker	  pasientene	  raskt	  etter	  
innleggelsen.	  
	  
Vakthavende	  lege	  rekvirerer	  blod-­‐og	  urinprøver	  ved	  innleggelse	  (delvis	  ferdig	  
utfylte	  skjemaer	  ligger	  i	  medisinsk	  ekspedisjon	  over	  grønne	  skjemaer).	  Dersom	  
pasienten	  står	  fast	  på	  medisiner	  ved	  innleggelse,	  føres	  dette	  opp	  på	  
blodprøverekvisisjonen.	  Laboratoriet	  i	  Trondheim	  vil	  i	  tillegg	  til	  
rusmiddelanalysen	  gjerne	  analysere	  nivå	  av	  evt.	  forordnet	  psykofarmaka.	  Det	  
er	  derfor	  svært	  viktig	  å	  føre	  opp	  når	  siste	  dose	  er	  inntatt.	  Blodprøven	  skal	  i	  
utgangspunktet	  tas	  medikamentfastende	  morgenen	  etter	  innleggelse.	  Ved	  fast	  
medisinering,	  gi	  kveldsmedisin	  som	  vanlig.	  Dersom	  det	  i	  akutt	  situasjonen	  
trengs	  evt.medisinering	  før	  blodprøve	  er	  tatt,	  bruk	  fortrinnsvis	  benzodiazepiner	  
for	  å	  unngå	  interaksjonsproblematikk	  analysemessig.	  Innkomstblodprøver	  
rekvireres	  på	  sykehusets	  laboratorieskjema	  som	  vanlig,	  husk	  å	  rekvirere	  	  ALAT	  
og	  gammaGT	  på	  prosjektpasientene.	  
Avdelingens	  ansvar	  er	  å	  følge	  opp	  at	  blod-­‐og	  urinprøvene	  tas.	  
Urinprøve	  tas	  så	  raskt	  etter	  innleggelse	  som	  mulig	  (overvåket	  prøve,	  se	  eget	  
skriv).	  Urinprøve	  og	  rekvisisjon	  leveres	  til	  laboratoriet	  umiddelbart.	  Etter	  kl.15	  
og	  i	  helger	  settes	  urinprøven	  i	  kjøleskapet	  på	  laboratoriet.	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Blodprøver	  tas	  altså	  morgenen	  etter	  innleggelse	  (obs.max.	  24	  timer	  etter	  
innleggelsen).	  I	  helger	  og	  på	  helligdager	  tas	  blodprøver	  av	  Tone	  Lykke-­‐Enger	  
eller	  Valborg	  Helseth.	  
Blod-­‐og	  urinprøver	  i	  prosjektet	  merkes	  på	  vanlig	  måte	  med	  navn	  og	  
fødselsdato.	  Prøvene	  sendes	  ikke	  inn	  til	  analyse	  før	  pasienten	  har	  samtykket	  i	  å	  
bli	  med	  i	  studien.	  Analysesvarene	  behandles	  konfidensielt,	  kun	  prosjektleder	  og	  
prosjektmedhjelper	  får	  tilgang	  til	  disse.	  Det	  er	  viktig	  at	  pasienten	  opplyses	  om	  
konfidensialiteten.	  
Informasjonsskriv	  og	  samtykkeerklæring	  vedlegges	  til	  orientering.	  
	  
Denne	  studien	  er	  helt	  avhengig	  av	  innsats	  og	  positiv	  holdning	  fra	  mange	  
parter.	  Sykehuset	  har	  behov	  for	  de	  opplysningene	  studien	  kan	  gi.	  
Takk	  for	  innsatsen!	  
	  
Med	  hilsen	  Valborg	  Helseth,	  prosjektleder	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REGISTRERINGSSKJEMA	  
Vakthavende	  lege	  /	  akuttavdeling:	  (dette	  skjema	  blir	  liggende	  i	  akuttavdeling	  til	  det	  hentes	  
av	  prosjektleder)	  
Registrering	  for	  prosjektet:	  Forløpsstudie	  av	  alkohol,	  medikament-­‐og	  narkotikamisbruk	  hos	  
innlagte	  pasienter	  med	  psykosediagnose	  
	  
Pasientnavn:…………………………………………………..	  
	  
Fødselsår:…………..	  
(født	  1961	  og	  senere)	  
	  
Psykose?	  	  	  	  	  	  	  
	   Sikker	  psykose	  
	   Meget	  sannsynlig	  psykose	  
	   Usikkert	  om	  psykose	  
	   Ikke	  psykose	  
	  	  	  	  	  	  	  	  	  	  	  
Hvis	  sikker	  psykose,	  meget	  sannsynlig	  psykose	  eller	  usikkert	  om	  psykose:	  Rekvirer	  blod-­‐og	  
urinprøver	  etter	  delvis	  ferdig	  utfylte	  skjemaer.	  Husk	  å	  føre	  opp	  fast	  medisinering	  og	  
evt.tidspunkt	  for	  siste	  dose	  psykofarmaka.	  
	  
	  
Urinprøve	  tatt:	  Dato:………	  	  	  	  	  Klokkeslett:………..	  
	  
Blodprøve	  tatt:	  Dato:………	  	  	  	  	  Klokkeslett:………..	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RUTINER	  VED	  OVERVÅKET	  URINPRØVETAKING	  i	  forbindelse	  med	  
rus/psykoseprosjektet.	  
	  
OBS!	  Det	  brukes	  egne	  urinprøveglass	  for	  dette	  prosjektet.	  De	  oppbevares	  i	  hver	  
akuttavdeling.	  	  
VIS	  TAKT	  OG	  RESPEKT	  OVERFOR	  PASIENTEN!	  Forklar	  at	  det	  er	  rutine	  med	  
overvåket	  urinprøve	  ved	  innkomst	  nå.	  
	  
Det	  er	  ønskelig	  at	  urinprøven	  tas	  så	  tett	  opp	  til	  innleggelsen	  som	  mulig.	  Den	  
kan	  tas	  når	  som	  helst	  på	  døgnet	  (trenger	  ikke	  være	  morgenurin),	  tas	  innen	  24	  
timer	  etter	  innleggelsen.	  Det	  anbefales	  at	  overvåket	  urinprøvetaking	  gjøres	  
rutinemessig	  i	  samband	  med	  den	  øvrige	  kontroll	  ved	  innleggelsen	  (jfr.	  
gjennomgang	  av	  pasientens	  eiendeler	  etc).	  Informer	  pasienten	  om	  at	  det	  pågår	  
et	  prosjekt	  der	  riktig	  urinprøvetaking	  er	  svært	  viktig.	  Fortell	  pasienten	  at	  
akkurat	  deres	  urinprøve	  er	  viktig	  for	  at	  sykehuset	  skal	  kunne	  forbedre	  rutinene	  
sine	  på	  sikt	  (som	  igjen	  er	  til	  det	  beste	  for	  pasientene).	  Hvis	  pasienten	  lurer	  på	  
hva	  prosjektet	  går	  ut	  på,	  fortell	  at	  de	  vil	  få	  mer	  informasjon	  dagen	  etter	  
innleggelse.	  Hvis	  pasienten	  virker	  skeptisk,	  legg	  da	  vekt	  på	  at	  urinprøven	  
behandles	  strengt	  konfidensielt,	  at	  det	  bare	  er	  prosjektleder	  som	  får	  vite	  
analyseresultatet.	  Fortell	  også	  at	  urinprøven	  ikke	  vil	  sendes	  til	  analyse	  før	  de	  
har	  samtykket	  etter	  samtale	  med	  prosjektleder.	  
	  
Før	  prøvetaking:	  
1. Merk	  hvit	  etikett	  med	  pasientnavn,	  fødselsdato,	  prøvedato,	  avdelingsnavn	  
og	  signatur.	  
2. Sjekk	  at	  rekvisisjonen	  er	  riktig	  utfylt.	  
	  
	  
Under	  prøvetaking:	  
1. Pasient	  og	  personale	  går	  inn	  på	  toalettet	  (best	  egnet	  er	  bad	  med	  toalett)	  	  
2. Pasienten	  får	  tildelt	  urinprøveglass	  og	  under	  diskret	  påsyn	  avlegger	  
pasienten	  urinen	  i	  glasset.	  Pasienten	  setter	  fra	  seg	  glasset	  på	  vasken	  og	  går	  
ut.	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3. Personalet	  tar	  med	  seg	  urinprøveglasset	  inn	  på	  skyllerommet	  og	  trekker	  opp	  
urinen	  i	  eget	  prøveglass	  (bruk	  vedlagte	  engangspipetter).	  Dette	  gjøres	  over	  
vasken	  på	  skyllerommet.	  Husk	  hansker.	  Pass	  på	  at	  prøveglasset	  ikke	  blir	  helt	  
fullt	  slik	  at	  lekkasjer	  unngås	  (glasset	  skal	  siden	  fryses	  ned	  på	  laboratoriet	  i	  
Trondheim).	  
	  
Etter	  prøvetaking:	  
Urinprøven	  merkes	  med	  hvit	  merkelapp.	  Urinprøven	  og	  rekvisisjonen	  leveres	  til	  
laboratoriet	  umiddelbart.	  Etter	  kl.	  15	  og	  i	  helger	  settes	  urinprøven	  i	  kjøleskapet	  
på	  laboratoriet.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  VHe	  mai	  01	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Forespørsel	  om	  å	  delta	  i	  kartleggingsundersøkelse	  
Forløpsstudie	  av	  alkohol,	  narkotika	  –	  og	  medikamentmisbruk	  hos	  innlagte	  
pasienter	  med	  mulig	  psykosediagnose	  
Prosjektleder:	  Valborg	  Helseth,	  overlege	  Blakstad	  sykehus	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Undersøkelsen	  skal	  prøve	  å	  gi	  svar	  på	  hvor	  mange	  av	  pasientene	  i	  aldersgruppen	  16-­‐30	  år	  
med	  psykisk	  lidelse	  som	  har	  et	  nåværende	  eller	  tidligere	  rusmisbruk.	  Psykisk	  lidelse	  og	  
samtidig	  rusmisbruk	  er	  et	  økende	  problem	  i	  dag.	  	  Kartlegging	  er	  viktig	  for	  å	  planlegge	  bedre	  
behandlingstilbud	  på	  sikt.	  Alle	  pasienter	  som	  innlegges	  med	  mistanke	  om	  psykose	  i	  denne	  
aldersgruppen	  kartlegges,	  helt	  uavhengig	  om	  det	  er	  opplysninger	  om	  rusmisbruk	  eller	  ikke.	  
Pasienter	  som	  inngår	  i	  studien	  gjennomgår	  to	  forskjellige	  intervjuer	  i	  tillegg	  til	  sykehusets	  
rutinemessige	  journalopptak.	  Det	  ene	  intervjuet	  er	  et	  diagnoseintervju	  basert	  på	  
vitenskapelig	  standardisering,	  det	  er	  noe	  mer	  omfattende	  enn	  et	  innkomstintervju.	  Dersom	  
det	  er	  nødvendig	  for	  riktig	  diagnostisering,	  kan	  også	  opplysninger	  fra	  sykehusets	  journal	  
innhentes.	  Den	  andre	  typen	  intervju	  kartlegger	  evt.	  rusmisbruk	  i	  tillegg	  til	  familiære/sosiale	  
forhold	  etc.	  Ved	  innleggelsen	  tas	  det	  blod-­‐	  og	  urinprøve	  som	  sjekkes	  med	  tanke	  på	  evt.	  
alkohol/narkotiske	  stoffer.	  Dersom	  pasienten	  har	  stått	  på	  medisin	  utskrevet	  av	  lege,	  vil	  også	  
nivået	  av	  medisin	  i	  blodet	  bli	  undersøkt.	  Disse	  prøvene	  inngår	  i	  sykehusets	  rutinemessige	  
laboratorieprøver	  ved	  innkomst.	  Ved	  utskrivning	  gjentas	  diagnoseintervjuet	  for	  å	  se	  om	  det	  
er	  endringer	  siden	  innkomst.	  	  
Deretter	  vil	  det	  følges	  opp	  med	  intervju	  ½	  år	  etter	  den	  første	  kartleggingen.	  Dette	  
oppfølgingsintervjuet	  legges	  opp	  slik	  at	  det	  verken	  økonomisk	  eller	  praktisk	  blir	  noen	  
belastning	  for	  den	  enkelte.	  Samtidig	  tas	  nye	  blod-­‐	  og	  urinprøver.	  Opplysninger	  om	  evt.	  
rusmisbruk	  bringes	  ikke	  videre	  av	  prosjektleder.	  Hensikten	  med	  oppfølgingsundersøkelsen	  er	  
å	  følge	  med	  på	  hvordan	  det	  går	  med	  pasienter	  som	  ble	  innlagt	  Blakstad	  sykehus	  i	  en	  bestemt	  
tidsperiode.	  Slike	  undersøkelser	  er	  viktig	  for	  å	  kunne	  utvikle	  behandlingsopplegg	  som	  stadig	  
kan	  bli	  bedre	  for	  pasientene.	  	  
ALLE	  OPPLYSNINGER	  SOM	  GIS	  I	  DENNE	  UNDERSØKELSEN	  ER	  TAUSHETSBELAGTE	  OG	  ALLE	  
DATA	  BEHANDLES	  KONFIDENSIELT.	  
Ved	  prosjektavslutning	  blir	  alle	  data	  anonymisert.	  	  
I	  skriftlige	  rapporter	  fra	  prosjektet	  blir	  alle	  data	  anonymisert.	  
Behandlingen	  som	  gis	  under	  oppholdet	  følger	  sykehusets	  vanlige	  prosedyrer	  uavhengig	  om	  
pasienten	  inngår	  i	  studien	  eller	  ikke.	  	  
	  
Kontaktperson:	  Valborg	  Helseth,	  Blakstad	  sykehus,	  pb.143,	  1371	  Asker	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tlf.	  66751505	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SAMTYKKEERKLÆRING	  
Prosjekt:	  Forløpsstudie	  av	  alkohol,	  narkotika	  –	  og	  medikamentmisbruk	  hos	  
innlagte	  pasienter	  med	  mulig	  psykosediagnose	  
	  
Prosjektleder:	  Valborg	  Helseth,	  overlege	  Blakstad	  sykehus	  
	  
Jeg	  er	  villig	  til	  å	  bli	  intervjuet	  av………………………………….(navn	  på	  
intervjuer)	  i	  en	  undersøkelse	  for	  å	  kartlegge	  evt	  rusmisbruk	  hos	  en	  
gruppe	  innlagte	  pasienter.	  
Jeg	  er	  blitt	  orientert	  om	  hensikten	  med	  og	  innholdet	  i	  intervjuene	  
samt	  den	  rutinemessige	  blod-­‐og	  urinprøvetagingen.	  
Jeg	  er	  orientert	  om	  at	  alle	  opplysninger	  jeg	  gir,	  vil	  bli	  behandlet	  
strengt	  konfidensielt.	  Opplysningene	  som	  gis	  vil	  ikke	  på	  noen	  måte	  
virke	  negativt	  inn	  i	  forhold	  til	  mitt	  opphold	  på	  sykehuset.	  
Behandlingen	  på	  sykehuset	  vil	  bli	  den	  samme	  om	  jeg	  blir	  med	  i	  
undersøkelsen	  eller	  ikke.	  
Jeg	  er	  også	  orientert	  om	  at	  deltagelse	  i	  kartleggingsstudien	  er	  frivillig	  
og	  at	  jeg	  derfor	  når	  som	  helst	  kan	  trekke	  meg	  fra	  videre	  intervjuer.	  
	  
	  
Sted:………………………………	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Dato:…………	  
	  
Navn:…………………………………………………(blokkbokstaver)	  
Signatur:…………………………………………….	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Forespørsel om deltakelse i forskningsprosjektet 
”PSYKOSER OG STEMNINGSLIDELSER  
MED RUSMIDDELBRUK” 
Bakgrunn 
Dette er et spørsmål til deg om å delta i en forskningsstudie for å utvikle 
kartleggings– og diagnoseverktøy som tar hensyn til de diagnoseproblemene som 
kan oppstå når pasientene bruker ulike rusmidler (dvs. alkohol, medikamenter, 
narkotika). Det er ofte usikkerhet rundt hvilke psykiske symptomer/plager som evt. 
kan skyldes rusmidlenes virkning – og hvilke symptomer som vil være tilstede også 
uten bruk av rusmidler (og som eventuelt forverres av rusmidler). Utvikling av et 
bedre diagnoseverktøy er derfor viktig for å gjøre denne usikkerheten mindre når 
man gir pasienter en diagnose. Det mest omfattende diagnoseintervjuet som hittil 
er utviklet er PRISM (Psychiatric Research Interview for Substance and Mental 
Disorders) som er utviklet ved Columbia-universitetet i USA. Senter for Rus- og 
Avhengighetsforskning ved Universitetet i Oslo, ved stipendiat Valborg Helseth, er 
ansvarlig for studien og ønsker nå å teste ut den første norske PRISM versjonen 
ved Blakstad sykehus. Vi ønsker også å kunne utarbeide en oversikt over 
forekomsten av rusmiddelbruk hos akuttinnlagte pasienter. 
Hva innebærer studien? 
PRISM vil brukes for å intervjue pasienter som innlegges ved akuttavdelingen 
Blakstad sykehus. Intervjuet er vitenskapelig standardisert og mer omfattende enn 
et innkomstintervju. Opplysninger som samles inn er en nøyaktig kartlegging av 
rusmiddelbruk (tidligere og nåværende), psykiatrisk diagnose og eventuelle tidligere 
straffbare forhold som kan belyse diagnostiseringen nærmere. Ved gjennomført 
intervju utbetales et honorar på kr. 300 fordi du bidrar til metodeutprøving i norsk 
rus- og psykiatriforskning. 
Før PRISM intervjuet kommer vi til å be deg fylle ut to kortfattete spørreskjemaer 
om rusmiddelbruk. 
Hva skjer med informasjonen om deg? 
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i 
hensikten med studien. Medarbeiderne i studien har taushetsplikt. Alle 
opplysningene vil bli behandlet uten navn og fødselsnummer/direkte 
gjenkjennende opplysninger. En kode knytter deg til dine opplysninger gjennom en 
navneliste. Det er kun autorisert personell knyttet til prosjektet som har adgang til 
navnelisten og som kan finne tilbake til deg. Det vil ikke være mulig å identifisere  
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deg i resultatene av studien når disse publiseres. Hvis du sier ja til å delta i studien, 
har du rett til å få innsyn i hvilke opplysninger som er registrert om deg. Du har 
videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Du 
kan når som helst få dine opplysninger slettet ved å kontakte prosjektleder. Bare 
medarbeidere som er direkte knyttet til prosjektet har tilgang til datamaterialet. 
Dersom en oppfølgingsstudie blir aktuelt senere, vil du bli kontaktet med en 
forespørsel om deltakelse i god tid før studien starter. Datamaterialet og navneliste 
blir oppbevart ved Universitetet i Oslo og blir senest slettet i 2020. 
Frivillig deltakelse 
Det er frivillig å delta i studien. Dersom du ikke ønsker å delta, trenger du ikke å 
oppgi noen grunn, og det får ingen konsekvenser for den videre behandlingen du 
får ved sykehuset. Du kan når som helst trekke deg fra studien. Deltakelse i studien 
kan bare få innvirkning på behandlingen dersom du ønsker at resultatet av 
diagnoseintervjuet formidles til behandleren din ved sykehuset.  
Dersom du ønsker å delta, undertegner du samtykkeerklæringen nedenfor. Om du 
nå sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker 
din øvrige behandling på sykehuset. Dersom du senere ønsker å trekke deg, kan du 
kontakte stipendiat/overlege Valborg Helseth (tlf. 66 75 19 10 / 23 36 89 34). 
 
Samtykkeerklæring: Jeg er villig til å delta i studien 
 
 
--------------------------------------------------------------------- 
(Signert av prosjektdeltaker, dato) 
Jeg bekrefter å ha gitt 
informasjon om studien: 
 
--------------------------------------
---------------- (Signert, rolle i 
studien, dato)  
 
Prosjektdeltaker er vurdert som samtykkekompetent i 
forhold til deltakelse i studien 
 
--------------------------------------------------------------------- 
(Signert av faglig ansvarlig, dato) 
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Protokoll	  for	  prosjektet:	  Psykoser	  og	  stemningslidelser	  med	  rusmiddelbruk;	  utprøving	  av	  det	  
diagnostiske	  intervjuet	  Psychiatric	  Research	  Interview	  for	  Substance	  and	  Mental	  Disorders	  (PRISM)	  
	  
Prosjektleder:	  Valborg	  Helene	  Helseth,	  klinisk	  stipendiat	  UiO/overlege	  Sykehuset	  Asker	  og	  Bærum	  HF	  
divisjon	  psykisk	  helse	  
	  
TIDSPUNKT	   TILTAK	   ANSVARLIG	  
Innen	  ett	  døgn	  etter	  
innleggelse	  
Inklusjonsvurdering:	  	  
Pasienter	  18-­‐65	  år	  
• Psykose	  (positive	  psykotiske	  symptomer	  
og/eller	  tidligere	  psykosediagnose)	  
og/eller	  
• Stemningslidelse	  
	  
Prosjektleder	  og	  vakthavende	  
lege	  
Innen	  ett	  døgn	  etter	  
innleggelse	  
Eksklusjonsvurdering:	  	  
• Språkproblemer	  
• Stor	  kognitiv	  svikt	  
• Organisk	  lidelse	  som	  påvirker	  utfall	  av	  
intervju	  
	  
Prosjektleder	  og	  vakthavende	  
lege	  
Innen	  tre	  døgn	  etter	  
innleggelse	  
Screening:	  
AUDIT	  (Alcohol	  Use	  Disorder	  Identification	  Test)	  
DUDIT	  (Drug	  Use	  Disorder	  Identification	  Test)	  
Prosjektleder	  og	  
”skjemaansvarlig”	  i	  
avdelingen	  
Etter	  screening	   Informasjon	  om	  prosjektet	  og	  
samtykkeerklæring	  
	  
Prosjektleder	  og	  
prosjektmedarbeidere	  
Når	  samtykke	  er	  gitt	  og	  
pasienten	  er	  klinisk	  
tilgjengelig	  
PRISM	  (Psychiatric	  Research	  Interview	  for	  
Substance	  and	  Mental	  Disorders)	  intervju	  
	  
Prosjektleder	  og	  
prosjektmedarbeidere	  
Når	  intervjuet	  er	  
ferdigkodet	  
Evt.	  journal	  informasjon	  om	  PRISM	  resultat	  	  
(forutsatt	  at	  pasienten	  har	  gitt	  skriftlig	  tillatelse)	  
Prosjektleder	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Informasjon	  til	  Avdeling	  for	  akuttpsykiatri	  om	  forskningsprosjektet	  	  
”Psykoser	  og	  stemningslidelser	  med	  rusmiddelbruk;	  utprøving	  av	  det	  
diagnostiske	  intervjuet	  Psychiatric	  Research	  Interview	  for	  Substance	  and	  Mental	  
Disorders	  (PRISM)”	  
	  
Vi	  ønsker	  å	  undersøke	  pasienter	  mellom	  18	  og	  65	  år	  som	  innlegges	  p.g.a.	  
psykose	  og/eller	  stemningslidelse	  og	  som	  har	  brukt	  rusmidler	  siste	  måned	  før	  
innleggelsen.	  
For	  inklusjon	  i	  psykosegruppen	  kreves	  positive	  psykotiske	  symptomer	  og/eller	  
tidligere	  diagnostisert	  psykotisk	  lidelse.	  	  
I	  stemningslidelsegruppen	  inkluderes	  pasienter	  med	  
depresjon/dystymi/cyclotymi/hypomani/mani.	  
Med	  rusmiddelbruk	  menes	  bruk	  av	  alkohol,	  narkotiske	  stoffer	  og/eller	  bruk	  av	  
medikamenter	  utover	  det	  som	  er	  forskrevet	  av	  lege.	  
	  
Formålet	  med	  prosjektet	  er	  en	  grundig	  diagnostisering	  av	  pasienter	  med	  
kompliserende	  rusmiddelbruk.	  Vi	  ønsker	  å	  finne	  mer	  ut	  av	  hvor	  mange	  av	  
pasientene	  som	  har	  rusmiddelinduserte	  lidelser	  og	  hvor	  mange	  som	  har	  
primær	  psykiatrisk	  sykdom	  komplisert	  med	  rusmiddelproblemer.	  
Overlege	  Jon	  Johnsen,	  overlege	  Tone	  Lykke-­‐Enger	  og	  stipendiat/overlege	  
Valborg	  Helseth	  vil	  gjennomføre	  PRISM	  intervju	  på	  pasientene.	  Dette	  intervjuet	  
er	  konstruert	  slik	  at	  man	  tar	  hensyn	  til	  de	  diagnostiske	  problemene	  som	  
oppstår	  når	  pasienter	  bruker	  ulike	  rusmidler.	  
Forut	  for	  PRISM	  intervjuet	  skal	  det	  gjøres	  en	  rask	  screening	  på	  rusmiddelbruk	  
(selvutfyllingsskjemaer).	  Vi	  vil	  sette	  stor	  pris	  på	  hjelp	  fra	  miljøkontaktene	  for	  å	  
sikre	  at	  aktuelle	  pasienter	  fyller	  ut	  disse	  skjemaene.	  Trine	  Asskildt	  vil	  sammen	  
med	  oss	  sørge	  for	  at	  aktuelle	  pasienter	  får	  skjemaene.	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Selvutfyllingsskjema	  for	  alkohol	  er	  AUDIT,	  tilsvarende	  for	  stoff	  og	  
medikamenter	  er	  DUDIT.	  
AUDIT	  fylles	  ut	  dersom	  det	  er	  opplysninger	  om	  alkoholbruk	  utover	  det	  som	  
anses	  som	  vanlig,	  sosial	  bruk.	  
DUDIT	  fylles	  ut	  dersom	  det	  har	  vært	  pille-­‐	  eller	  stoffmisbruk	  uavhengig	  av	  
mengden.	  	  
For	  at	  vi	  skal	  vite	  hvilke	  pasienter	  selvutfyllingsskjemaene	  gjelder	  for,	  kan	  dere	  
skrive	  med	  blyant	  pasientens	  initialer	  i	  omvendt	  rekkefølge	  (eks.	  Hans	  Norman	  
Olsen	  blir	  ONH	  o.s.v.).	  Vi	  vil	  siden	  pusse	  ut	  initialene	  og	  gi	  skjemaene	  et	  
referansenummer	  slik	  at	  skjemaene	  oppbevares	  avidentifisert.	  
	  
Vi	  ser	  fram	  til	  et	  hyggelig	  og	  godt	  samarbeid	  de	  neste	  månedene!	  
	  
Blakstad,	  15.november	  2007	  
	  
Med	  vennlig	  hilsen	  fra	  
Jon	  Johnsen,	  Tone	  Lykke-­‐Enger	  og	  Valborg	  Helseth	  
	  
Hvis	  dere	  har	  spørsmål,	  ikke	  nøl	  med	  å	  kontakte	  oss:	  
Valborg	  Helseth	  tlf	  	  66	  75	  19	  10	  eller	  90	  13	  87	  54	  
e-­‐post:	  vhelse@sabhf.no	  
Tone	  Lykke-­‐Enger	  tlf.	  97	  59	  71	  09	  
e-­‐post:	  tone.lykke-­‐enger@sabhf.no	  
Jon	  Johnsen	  tlf.	  91	  18	  54	  65	  
e-­‐post.	  jon.johnsen@sabhf.no	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SAMTYKKE-­‐ERKLÆRING	  
Prosjekt:	  PSYKOSER	  OG	  STEMNINGSLIDELSER	  MED	  SAMTIDIG	  RUSMIDDELBRUK	  
Utprøving	  av	  det	  diagnostiske	  intervjuet	  PRISM	  (Psychiatric	  Research	  Interview	  for	  
Substance	  and	  Mental	  Disorders)	  
	  
Prosjektleder:	  Valborg	  Helseth,	  Universitetet	  i	  Oslo	  /	  Sykehuset	  Asker	  og	  Bærum	  
	  
Jeg	  er	  villig	  til	  å	  bli	  intervjuet	  av	  ……………………………………….	  
(navn	  på	  intervjuer)	  i	  en	  undersøkelse	  hvor	  hensikten	  er	  å	  forbedre	  diagnostiseringen	  innen	  
rus/psykiatri	  feltet.	  
Jeg	  har	  mottatt	  skriftlig	  og	  muntlig	  informasjon	  og	  er	  villig	  til	  å	  delta	  i	  studien.	  
Jeg	  er	  orientert	  om	  at	  alle	  opplysningene	  jeg	  gir,	  vil	  bli	  behandlet	  strengt	  konfidensielt.	  
Opplysningene	  som	  gis,	  vil	  ikke	  på	  noen	  måte	  virke	  negativt	  inn	  i	  forhold	  til	  mitt	  opphold	  på	  
sykehuset.	  
Jeg	  er	  også	  orientert	  om	  at	  deltakelse	  i	  diagnosestudien	  er	  frivillig	  og	  at	  jeg	  derfor	  når	  som	  
helst	  kan	  trekke	  meg	  fra	  intervjuet.	  
	  
Sted:	  …………………	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Dato:	  ……..	  
Navn:	  …………………………………………….(blokkbokstaver)	  
Signatur	  …………………………………………	  
	  
	  
BEKREFTELSE	  
	  
Jeg	  bekrefter	  å	  ha	  gitt	  tilstrekkelig	  informasjon	  om	  studien:	  
…………………………………………………(dato,	  signatur)	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SAMTYKKE	  	  
I	  FORBINDELSE	  MED	  FORSKNINGSPROSJEKTET	  ”PSYKOSER	  OG	  
STEMNINGSLIDELSER	  MED	  RUSMIDDELBRUK”	  
	  
	  
Undertegnede	  ……………………….gir	  tillatelse	  til	  at	  totalskåren	  på	  	  
selvutfyllingsskjemaene	  for	  rus	  (AUDIT	  og	  DUDIT)	  sammen	  med	  
resultatet	  av	  diagnoseintervjuet	  PRISM	  føres	  inn	  i	  min	  pasientjournal	  
ved	  Sykehuset	  Asker	  og	  Bærum	  divisjon	  psykisk	  helse.	  
	  
	  
	  
	  
Dato:……………	  
	  
	  
	  
Underskrift:	  …………………………………	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AUDIT Alcohol Use Disorder Identification Test 
Saunders, JB., Aasland O.G., Babor T:F., De La Fuenta J.R., Grant, M. 
 
Her er noen spørsmål om din bruk av alkohol siste 12 måneder. Vi er takknemlige om 
du svarer så grundig og ærlig som mulig ved å markere det alternativ som gjelder for deg.  
 
1. Hvor ofte drikker du alkohol? 
 
Aldri 
 
  
Månedlig eller 
sjeldnere 
  
2-4 ganger i 
måneden 
  
2-3 ganger 
i  uken 
  
4 ganger i 
uken eller mer 
  
 
2. Hvor mange alkoholenheter tar 
du på en typisk drikkedag? 
(En alkoholenhet er: 1 glass vin, 
1 drink, en liten flaske pils, 33 l) 
1-2  
 
  
3-4   
 
  
5-6  
 
  
7-9  
 
  
10 eller flere 
 
  
 
3. Hvor ofte drikker du seks 
alkoholenheter eller mer på en 
gang?  
Aldri 
 
 
  
Sjeldnere enn  
månedlig 
 
  
Noen ganger  
i måneden  
 
  
Noen 
ganger i 
uken 
  
Daglig eller 
nesten  
daglig 
  
 
4. Hvor ofte har du i løpet av 
det siste året ikke vært i stand 
til å stoppe å drikke alkohol 
etter at du hadde begynt? 
Aldri 
 
 
  
Sjeldnere enn 
månedlig 
 
  
Noen ganger  
i måneden 
 
  
 
Noen 
ganger i 
uken 
  
Daglig eller 
nesten 
daglig 
  
5. Hvor ofte har du i løpet av 
det siste året unnlatt å gjøre 
ting du skulle gjort på grunn av 
drikking? 
Aldri 
 
 
  
Sjeldnere enn 
månedlig 
 
  
Noen ganger  
i måneden 
 
  
Noen 
ganger i 
uken 
  
Daglig eller 
nesten 
daglig 
  
 
6. Hvor ofte har du i løpet av 
det siste året trengt en drink om 
morgenen for å komme i gang 
etter sterk drikking dagen før?  
Aldri 
 
 
 
  
Sjeldnere enn  
månedlig 
 
 
  
Noen ganger  
i måneden 
 
 
  
Noen 
ganger i 
uken 
 
  
 
Daglig eller 
nesten 
daglig 
 
  
7. Hvor ofte har du  i løpet av 
det siste året hatt skyldfølelse 
eller samvittighetsnag på grunn 
av drikking?  
Aldri 
 
 
 
  
Sjeldnere enn 
månedlig 
 
 
  
Noen ganger  
i  måneden 
 
 
  
Noen 
ganger i 
uken 
 
  
Daglig eller 
nesten 
daglig 
 
  
 
8. Hvor ofte har du i løpet av 
det siste året ikke husket hva 
som hendte kvelden før på 
grunn av drikking? 
 
Aldri 
 
 
  
Sjeldnere enn 
månedlig 
 
  
Noen ganger  
i måneden 
 
  
Noen 
ganger i 
uken 
  
Daglig eller 
nesten 
daglig 
  
9. Har du eller noen andre blitt 
skadet som følge av drikkingen 
din? 
Nei 
 
  
 Ja, men ikke det 
siste året 
  
     Ja, det siste  
året 
  
 
10. Har en slektning eller venn, 
lege eller sykepleier, eller noen 
andre engstet seg over 
drikkingen din, eller antydet at 
du burde redusere?  
 
Nei 
 
  
 Ja, men ikke i 
løpet av siste år 
  
 Ja, i løpet av 
siste år 
  
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DUDIT Drug Use Disorders Identification Test 
Her vil vi stille deg noen spørsmål om bruk av stoff. Vi er takknemlige for at du svarer 
grundig og ærlig på de alternativene som passer for deg. 
 
Mann   
 
Kvinne    Alder:  
1. Hvor ofte bruker du andre 
rusmidler/stoff enn alkohol? 
(Se listen over andre rusmidler) 
Aldri 
 
  
1 gang i måneden 
eller sjeldnere 
  
2-4 ganger 
i måneden 
  
2-3 ganger i 
uken 
  
4 ganger i uken 
eller mer 
  
 
2. Bruker du flere typer stoff 
samtidig? 
Aldri 
 
  
1 gang i måneden 
eller sjeldnere 
  
2-4 ganger 
i måneden 
  
2-3 ganger i 
uken 
  
4 ganger i uken 
eller mer 
  
 
3. Når du bruker stoff, hvor 
mange ganger i løpet av en 
typisk dag tar du da stoff? 
0 
  
1-2 
  
3-4 
  
5-6 
  
7 eller flere 
  
 
4. Hvor ofte blir du kraftig 
påvirket av stoff? 
Aldri 
 
  
Sjeldnere enn en 
gang i måneden 
  
Hver  
måned 
  
Hver uke 
 
  
Daglig eller nesten 
hver dag 
  
 
5. Har du det siste året opplevd 
at suget etter stoff har vært så 
sterkt at du ikke kunne stå i 
mot? 
Aldri 
 
  
Sjeldnere enn en 
gang i måneden 
  
Hver  
måned 
  
Hver uke 
 
  
Daglig eller nesten 
hver dag 
  
 
6. Har det i løpet av det siste 
året hendt at du ikke har klart å 
slutte å ta stoff når du først har 
begynt?  
Aldri 
 
  
Sjeldnere enn en 
gang i måneden 
  
Hver  
måned 
  
Hver uke 
 
  
Daglig eller nesten 
hver dag 
  
 
7. Hvor ofte i løpet av det siste  
året unnlot du å gjøre ting du 
skulle ha gjort p.g.a. stoffbruk?  
Aldri 
 
  
Sjeldnere enn en 
gang i måneden 
  
Hver  
måned 
  
Hver uke 
 
  
Daglig eller nesten 
hver dag 
  
 
8. Hvor ofte i løpet av det siste 
året har du startet dagen med å 
ta stoff etter stort stoffinntak 
dagen før? 
Aldri 
 
  
Sjeldnere enn en 
gang i måneden 
  
Hver  
måned 
  
Hver uke 
 
  
Daglig eller nesten 
hver dag 
  
9. Hvor ofte i løpet av det siste 
året har du hatt skyldfølelse 
eller dårlig samvittighet fordi du 
har brukt stoff? 
Aldri 
 
  
Sjeldnere enn en 
gang i måneden 
  
Hver  
måned 
  
Hver uke 
 
  
Daglig eller nesten 
hver dag 
  
10. Har du eller noen andre blitt 
skadet (psykisk eller fysisk) på 
grunn av din bruk av stoff? 
Nei 
 
  
 Ja, men ikke 
det siste året 
  
     Ja, det siste  
året 
  
 
11. Har en slektning eller venn, 
lege eller annen helsearbeider 
(eller noen andre), vært 
bekymret over din bruk av stoff, 
eller foreslått at du bør slutte 
med stoff?  
 
Nei 
 
  
  
Ja, men ikke 
det siste året 
  
      
Ja, det siste  
året 
  
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LISTE OVER NARKOTISKE STOFFER (OBS! IKKE ALKOHOL)	  
 
Sett et kryss ved de stoffene du har brukt det siste året. 
 
Skriv på linja under hvilket stoff/rusmiddel  du har brukt mest det siste året?  
 
…………………………………………………………………………….. 
	  
Cannabis	  
Marijuana 
Hasj 
Hasjolje 
 
 
 
 
	  
Amfetamin	  
Metamfetamin 
Fenmetralin 
Khat 
Betelnøtt 
Ritalin	  
Kokain	  
Crack 
Freebase 
Kokablad	  
Opiater	  
Røykeheroin 
Heroin 
Opium	  
Hallucinogener	  
Ecstasy 
LSD 
Meskalin 
Peyote 
PCP 
Psylocibin 
DMT	  
Løsningsm
iddel	  
Thinner 
Trikloretylen 
Bensin 
Gas 
Solution 
Lim 
	  
GHB	  och	  
øvrige	  
GHB 
Anabola 
steroider 
Lystgasss 
Amylnitrat 
(poppers) 
Antikolinergika	  
	  
	  
 
TABLETTER – LEGEMIDLER 
Tabletter regnes som narkotiske stoffer når du tar: •	  legemidler mer eller oftere enn legen har foreskrevet •	  tabletter for å ha det moro, føle deg bra, bli "høy”, eller prøve ut effekten av dem •	  tabletter som du har fått av en slektning eller venn •	  tar tabletter som du har kjøpt "svart" eller stjålet 
 
 
Beroligende	  	   legemidler	   Og/eller	  sovetabletter	   Smertestillende	   legemidler	    
Alprazolam 
Apodorm 
Apozepam 
Alopam 
Atarax 
Diazepam 
Dormicum 
Fenemal 
Flunitrazepam 
Halcion 
Heminevrin 
Imovane 
Mogadon 
Nitrazepam 
Oxazepam 
Persedon 
Rohypnol 
Serepax 
 
Sobril 
Somadril 
Sonata 
Stesolid 
Stilnoct 
Temesta 
Triazolam 
Valium 
Xanor 
Adrinex 
Coccelana 
Citodon 
Dexodon 
Dexofen 
Dilauid 
Distalgesic 
Dolcontin 
Doleron 
Dolotard 
Doloxene 
 
Durogesic 
Fortalgesic 
Hydromorfo
nklorid 
Ketodur 
Ketogan 
Kodein 
Metadon 
Morfin 
Scopolamin 
Nobligan 
 
Norgesic 
Oxikon 
Panocod 
Paraflex 
comp 
Spasmofen 
Subutex 
Temgesic 
Tiparol 
Tradolan 
Tramadul 
Treo comp 
 
 
 
Tabletter regnes ikke som narkotiske stoffer når de er foreskrevet av 
lege og du tar dem slik legen sier at du skal (både mengde og 
hyppighet). 
	  
